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ABSTRACT 
Alzheimer’s and Parkinson’s disease (AD and PD, respectively) are the two 
most common neurodegenerative diseases. Currently, no interventions have been 
successful in stopping the progression of these diseases. Here, we utilize two 
independent strategies: the use of natural products and repurposed pharmaceuticals 
to target neuroinflammation in models of neurodegeneration.  
 Natural products have been used for their medicinal properties for centuries in 
traditional eastern medicine practices. Mucuna pruriens (Mucuna) is a well-known 
natural source of levodopa, typically prescribed in Ayurveda for PD. A novel levodopa 
reduced seed extract exhibited protective effects against oxidative stress and PD 
specific toxic agents, both in vitro and in vivo. Further phytochemical investigation of 
our extract led to the isolation and identification of seven newly reported compounds. 
Isolates failed to protect against toxin inducers of PD in cellular models. These data 
support that our novel levodopa reduced seed extract, but not isolated compounds, 
protect against toxin-induced models of PD. 
 The Mediterranean diet, which is primarily composed of polyphenols, has 
gained considerable interest in the management of age-related diseases. Therefore, 
common polyphenols classes, isoflavones, and lignans with their gut-derived 
microbial metabolites were evaluated. Polyphenol microbial metabolites generally 
showed greater blood-brain barrier permeability and protection against oxidative 
stress, as compared to their parent compounds. Moreover, polyphenol microbial 
metabolites may heavily contribute to the beneficial effects of polyphenol enriched 
diets in disease prevention.  
 Repurposing pharmaceuticals is an approach that allows for expedited drug 
discovery to fast track pharmaceuticals to a new targeted patient population. Here, 
we analyze direct thrombin inhibitor, dabigatran etexilate (Pradaxa®), against 
  
neuroinflammation in AD and PD models. In a Drosophila melanogaster transgenic 
model of PD, dabigatran treatment improved locomotor ability and reduced 
neuroinflammatory markers in males. Further, in a tau-based animal model of AD 
short-term treatment with dabigatran modulates expression of proteins related to 
antioxidants, mitogen-activated protein kinases, tau, thrombin, and oxidative stress. 
Taken together, these data indicate short-term treatment with a direct thrombin 
inhibitor modulates protein expression in the brains of aged Tg4510 mice. These 
findings support our hypothesis that targeting thrombin, a key mediator of 
neuroinflammation and neurotoxicity may be effective in reducing neuroinflammation 
in neurodegenerative diseases.  
 Our results indicate two common drug discovery methods, namely, 
investigation of natural products and repurposing pharmaceuticals, may provide 
insights for targeting neuroinflammation in neurodegenerative diseases. Further 
research should focus on moving these therapeutics through the drug discovery 
pipeline to the patient population.   
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PREFACE  
The following dissertation is presented in manuscript format which creates four major 
chapters. The publication status of each manuscript is as follows:  
Chapter 1: Generate and evaluate the bioactivity of Levodopa-reduced Mucuna 
pruriens extract and isolated compounds in cellular models of PD  
Manuscript 1: Levodopa-reduced Mucuna pruriens seed extract shows 
neuroprotective effects against Parkinson’s disease in murine microglia and 
human neuroblastoma cells, Caenorhabditis elegans, and Drosophila 
melanogaster. Published in Nutrients, 2018.  
Manuscript 2: Isolation and identification of compounds from Mucuna pruriens 
seeds. Under review at Chemistry of Natural Products, Nov 2019. 
Chapter 2: Examine common polyphenols and corresponding gut-derived 
microbial metabolites for blood brain barrier permeability, reduction of 
neuroinflammation and protection in cellular and Drosophila melanogaster PD 
models 
Manuscript 3: Polyphenol microbial metabolites exhibit gut and blood-brain 
barrier permeability and protect microglia against LPS-induced inflammation. 
Published in Metabolites, 2019.  
Manuscript 4: Phytoestrogen, Equol, provides protection against toxin-induced 
models of Parkinson’s disease. In preparation.  
Chapter 3: Explore the protective ability of direct thrombin inhibitor, 
Dabigatran, against neuroinflammation and motor impairments in Drosophila 
melanogaster models of PD 
Manuscript 5: Direct thrombin inhibitor, Dabigatran, protects against 
neuroinflammation in LRRK2 transgenic Drosophila melanogaster model of 
Parkinson’s disease. In preparation. 
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Chapter 4: Investigate Dabigatran etexilate influence on oxidative stress and 
neuroinflammation in aged, transgenic tau AD mouse model 
Manuscript 6: Direct thrombin inhibitor, dabigatran etexilate, reduces oxidative 
stress in vivo in a transgenic mouse model of Alzheimer’s disease. In 
preparation. 
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JUSTIFICATION OF RESEARCH 
 
 Neurodegenerative diseases are broadly defined as age-related disorders 
where cells of the nervous system gradually lose function. The two most common 
neurodegenerative diseases are Alzheimer’s (AD) and Parkinson’s disease (PD). In 
2016, nearly 5.4 million Americans were affected by AD; PD is expected to affect 
nearly 930,000 individuals by 20201,2. Although these diseases present vastly 
different symptoms, there are several commonalities. For instance, both diseases are 
associated with protein aggregations, genetic predispositions, mitochondrial 
dysfunction and neuroinflammation, all processes which heavily contribute to 
neuronal death3.  
Alzheimer’s Disease 
AD typically affects the elderly population, characterized by episodic memory 
deficits later progressing to full-blown dementia with language impairment and severe 
behavioral changes4. Specific causes of AD are not known; however, lifestyle, 
genetics, and environment are all identified as risk factors5,6. Pathologically, AD is 
identified postmortem by the presence of b-amyloid (Ab) plaques and neurofibrillary 
tangles, comprised of Ab fragments and hyperphosphorylated tau, respectively. The 
AD brain exhibits extensive neuronal death, believed to originate in the hippocampus 
and move to adjacent brain regions4. For decades, the amyloid hypothesis has 
dominated AD research. This hypothesis suggests there is a cascading event that 
beings with Ab accumulation leading to neurofibrillary tangles, which in turn disrupts 
synaptic and neuronal function7. Pharmaceutical interventions targeting disease 
pathogenesis have not been successful in stopping the progression of the disease.  
It has become more widely accepted that AD is much more complicated than 
the original amyloid hypothesis. Research has shifted to explore age-related decline 
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through the influence of tau, inflammation, gut microbiota and vascular dysfunction in 
AD pathogenesis8–11. Our previous research has focused heavily on 
neuroinflammation induced by the activation of the vasculature. Driving this interest is 
the correlation of cardiovascular disease and vascular risk factors, such as 
hypertension and diabetes, with AD incidence rates6. Further, injury to the 
cerebrovasculature leads to the activation and dysfunction of brain endothelial cells12. 
In the AD brain, vascular activation has detrimental consequences for neuronal 
viability. Many vascular-derived factors, such as thrombin, are neurotoxic and likely 
critical in the pathogenesis of AD11,13,14.  
Currently, available medications target symptoms, but not disease pathology 
or progression. The two approved drug treatments for AD are inhibitors of 
cholinesterase and N-methyl-D-aspartate (NMDA) receptors; both exhibit modest 
beneficial effects on cognition5,15. Significant research has focused on identifying 
novel disease-modifying drugs, but there have been several failures in the clinic16. 
Current trends for AD research are now focusing on identifying biomarkers for earlier 
diagnosis and identifying interventions that aim to modify disease progression4,17. 
Continued AD research must identify new ways to modify disease progression and 
pathogenesis to drive the future of pharmaceutical developments.  
Parkinson’s Disease 
PD is characterized by irregular, uncontrolled movements, frequently 
presenting as resting tremors or dyskinesias. Pathological hallmarks include the loss 
of dopaminergic neurons in the substantia nigra and an abundance of a-synuclein 
aggregates, termed Lewy bodies, throughout the brain18. Direct causes of Parkinson’s 
disease are not known; however, a variety of genetic predispositions, gender, and 
environmental factors have been identified as contributors. At least 17 genetic 
mutations have been identified as contributing factors in PD including a-synuclein, 
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parkin, DJ-1, and leucine-rich repeat kinase 2 (LRRK2)18–20. Environmental exposure 
to pesticides, such as paraquat, and similarly structured chemical 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) can also result in symptoms indistinguishable from 
PD18–20. Interestingly, males are 1.5 times more likely to have PD than females, and 
incident rates in females increase dramatically after menopause, suggesting a 
protective role of estrogen21,22. 
Pharmaceutical interventions for PD have mainly focused on the 
replenishment of dopamine to reduce motor impairments. These pharmaceutical 
classes include catechol-O-methyl transferase (COMT) inhibitors, monoamine 
oxidase type B (MAO-B) inhibitors, dopamine agonists, and levodopa paired with a 
dopamine decarboxylase inhibitor23–25. Levodopa combination therapy limits the 
production of dopamine in the periphery and attempts to restore dopamine imbalance 
in the brain. Levodopa is then converted to dopamine by dopamine decarboxylase, 
increasing levels of dopamine in the affected brain regions26. Levodopa paired with a 
dopamine decarboxylase inhibitor is currently the standard of care for PD; however, 
with prolonged treatment, levodopa becomes less effective, and motor deficits can 
increase26. The aforementioned therapies are effective in some cases, but new 
formulations and administration routes are being explored to overcome problems of 
prolonged efficacy23. Surgical interventions have also been approved as therapies for 
PD. Deep brain stimulation using high-frequency stimulation in the subthalamic 
nucleus and globus pallidus internus exhibits improved motor control24,25. Similar to 
AD, available interventions cannot stop or prevent disease progression; therefore, it is 
essential to identify and target disease-modifying mechanisms. Current literature 
proposes the investigation of genetic mutations, mitochondrial function, 
neuroinflammation, and oxidative stress, among others18,26.   
 
 4 
 
Neuroinflammation in Alzheimer’s and Parkinson’s Diseases 
Neuroinflammation has been recognized as a major factor in AD and PD 
pathogenesis6,7,17,18,26–28. While these two diseases present quite differently, the 
neuroinflammatory response is similar3. Integral to the regulation of inflammation in 
the brain is the neurovascular unit (NVU). Astrocytes, microglia, neurons, pericytes, 
and endothelial cells collectively create the NVU that maintains normal cerebral blood 
flow and blood-brain barrier (BBB) functioning29. Under normal conditions, microglia, 
the major immune cells of the brain, work to detect pathogens or tissue damage and 
elicit a response to clear cellular debris and degenerating cells17. However, when 
microglia are continuously activated by external stimuli such as aggregated protein or 
foreign pathogens, this response can then exacerbate any present neuronal 
damage30. This toxic microglial inflammatory response includes the release of a 
variety of inflammatory mediators, such as chemokines, cytokines, cyclooxygenase-2 
(COX-2), inducible nitric oxide synthase (iNOS) and reactive mediators, namely, 
reactive oxygen species (ROS) and nitric oxide species (NOS)17,31,32. The chronic 
production of these inflammatory mediators increases oxidative stress and 
contributes to neuronal death. Although complex, neuroinflammation plays a major 
role in neurodegenerative diseases and has been identified as a worthy target for 
pharmaceutical interventions in neurodegenerative diseases.  
Therapeutic Strategies 
In recent years, big pharmaceutical companies such as Pfizer have shut down 
their neuroscience research groups. A major part of this is due to the lack of success 
in developing drugs to treat neurological diseases. Since 1990, there has been a 
decline in nervous system drugs, with fewer Phase I trial starts, as well as a greater 
probability of failure in Phase III33. The investigation of new therapeutics for central 
nervous system diseases has proven to be extremely cost and time ineffective. 
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Therefore, it is imperative to acknowledge and utilize methods that will reduce both 
factors. Herein, we investigate two commonly used drug discovery strategies: natural 
products and repurposing pharmaceuticals.  
Therapeutic Strategy I: Natural Products 
Plant-based approaches to medicine have been utilized for centuries. The 
generational knowledge of traditional Chinese medicine (TCM) and traditional Indian 
medicine (Ayurveda) have driven the investigation of natural sources to identify 
biologically active compounds34. Among these discoveries have come major medical 
advancements for cancer, hypertension, malaria, and pain, among others35. One of 
the most commonly known natural product derived pharmaceuticals is aspirin. Willow 
bark as a pain and fever reliever dates back more than 3,500 years. The active 
compound, salicylic acid, was initially identified in 1838. Scientists at Bayer then 
acetylated salicylic acid to create a more stable compound, now known as aspirin36. 
This story is not unique to aspirin, approximately 51% of all newly approved drugs 
from 1981 to 2014 were derived from or structurally related to a natural product37. 
Natural product, Gingko biloba, is an example that has been successful in mitigating 
the cognitive decline in animal models but has been controversial in AD clinical 
trials38–41. The success of natural products has been instrumental in the foundations 
of modern medicine and thus should not be ignored as a viable option for future 
therapeutic developments35,42.  
Mucuna pruriens is a legume common to southern China and eastern India, 
used heavily as a food source, and for the treatment of tremors43. Ayurveda 
traditionally used Mucuna to treat PD, as the beans are naturally high in levodopa44. 
This use of Mucuna pruriens led to further investigation of this medicinal plant. In two 
clinical trials, Mucuna pruriens preparations exhibited more rapid onset and more 
tolerable profiles as compared to levodopa paired with a dopamine decarboxylase 
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inhibitor, suggesting potential advantages of the natural product to the common 
pharmaceutical45,46. Multiple studies suggest that the anti-PD activity of Mucuna is 
entirely due to the presence of levodopa46–49. However, newer evidence also 
suggests that there may be bioactive compounds other than levodopa could provide 
neuroprotection50.  
Another interesting class of natural products, namely, polyphenols, exhibits a 
wide range of bioactive properties including antioxidant, anti-inflammatory, anti-
apoptotic and lipid-lowering properties51,52. Interestingly, the Mediterranean diet is 
characterized by a high intake of polyphenols and has been identified as a beneficial 
intervention for the management of cardiovascular disease, obesity and 
neurodegenerative diseases53–55. While polyphenols themselves may exhibit 
biological effects, it is generally considered that the consumed compounds get 
metabolized in the colon by microbiota to produce bioactive metabolites56–60. Two 
common classes of polyphenols: lignans and isoflavones are found primarily in 
flaxseed and soy, respectively. The common and prototypical dietary lignan, 
secoisolariciresinol (SECO), is known to be converted to the polyphenol microbial 
metabolites (PMM) enterodiol (ED) and enterolactone (EL)61. The isoflavones, 
genistein (GEN) and daidzein (DAI), are metabolized in the gut by intestinal microflora 
to produce equol (EQ)62. Isoflavones are structurally similar to estrogen, containing 3-
phenylchromen-4-one backbone, making them a curious class of compounds for PD 
research63. Additionally, GEN was identified as a potential nutraceutical for AD due to 
the ability to inhibit mitochondria-dependent apoptosis, and alleviate b-amyloid 
neurotoxicity, but failed in clinical trials64–66. Failing in the clinic may have been due to 
rapid metabolism into metabolites, therefore it would be of interest to examine gut 
microbial-derived metabolites. 
Therapeutic Strategy II: Repurposing Pharmaceuticals 
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Another promising strategy for new therapeutics is to repurpose “old” drugs. 
Repurposing pharmaceuticals is defined as determining alternative uses beyond the 
scope of the original indication67. This approach is advantageous as these 
therapeutics have been extensively studied for safety, pharmacokinetic profiles, bulk 
manufacturing, and in vitro and in vivo screening67. This strategy reduces risk, 
development time and costs, and provides a fast-track to the patient population68. 
Repurposing pharmaceuticals has been utilized to identify new therapies for cancer, 
depression, and schizophrenia, among others68–70. Aspirin is again a good example 
drug, as it has been re-purposed for several alternative therapeutic indications. 
Aspirin was initially FDA-approved to reduce pain and fevers. Recently, aspirin has 
been extensively studied for antiproliferative and anticancer activities71. Aspirin is 
effective in reducing cell viability in multiple subtypes of breast cancer cells72. In 
colorectal cancer patients, aspirin has shown improved survival rates73. In addition to 
cancer, aspirin has also been analyzed in combating fungal infections74. Moreover, 
recent studies have looked at repurposing approved antibiotics to reduce protein 
aggregation in neurodegenerative diseases75–77. Using pharmaceuticals to target 
diseases alternative to initial indications has proven a worthy mechanism to identify 
new therapies and should be continuously explored.  
Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim) is a commonly 
prescribed anticoagulant that directly inhibits thrombin. Vascular activation results in 
injured endothelial cells which upregulate the production of thrombin both in vivo and 
in vitro13,78,79. Elevated levels of thrombin can be neurotoxic through the interaction 
with protease-activated receptor 1 (PAR-1), leading to the release of reactive oxygen 
species (ROS) and increases in a large array of inflammatory proteins80,81. Increased 
levels of both thrombin and PAR-1 have been identified in both AD and PD82. 
Previous studies have identified that dabigatran treatment mitigates the neurotoxic 
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effects of thrombin13,83,84. Dabigatran etexilate also provides neuroprotection in a 
rotenone-induced rat model of PD through nuclear receptor-related 185.  
Dissertation Objective 
The following dissertation will propose new therapeutic strategies from natural 
products and pharmaceuticals to reduce neuroinflammation in AD and PD models. 
Outcomes will provide new insight into the current state for the protection against 
neuroinflammation.  
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Abstract 
 
Mucuna pruriens (Mucuna) has been prescribed in Ayurveda for various brain 
ailments including ‘kampavata’ (tremors) or Parkinson’s disease (PD). While 
Mucuna is a well-known natural source of levodopa (L-dopa), published studies 
suggest that other bioactive compounds may also be responsible for its anti-PD 
effects. To investigate this hypothesis, a L-dopa reduced (<0.1%) M. pruriens 
seeds extract (MPE) was prepared and evaluated for its anti-PD effects in cellular 
(murine BV-2 microglia and human SH-SY5Y neuroblastoma cells), 
Caenorhabditis elegans, and Drosophila melanogaster models. In BV-2 cells, MPE 
(12.5–50 μg/mL) reduced hydrogen peroxide-induced cytotoxicity (15.7−18.6%), 
decreased reactive oxygen species production (29.1−61.6%), and lowered 
lipopolysaccharide (LPS)-induced nitric oxide species release by 8.9–60%. MPE 
(12.5−50 μg/mL) mitigated SH-SY5Y cell apoptosis by 6.9−40.0% in a non-contact 
co-culture assay with cell-free supernatants from LPS-treated BV-2 cells. MPE 
(12.5−50 μg/mL) reduced 6-hydroxydopamine (6-OHDA)-induced cell death of 
SH-SY5Y cells by 11.85–38.5%. Furthermore, MPE (12.5−50 μg/mL) increased 
median (25%) and maximum survival (47.8%) of C. elegans exposed to the 
dopaminergic neurotoxin, methyl-4-phenylpyridinium. MPE (40 μg/mL) 
ameliorated dopaminergic neurotoxin (6-OHDA and rotenone) induced 
precipitation of innate negative geotaxis behavior of D. melanogaster by 35.3 and 
32.8%, respectively. Therefore, MPE contains bioactive compounds, beyond L-
dopa, which may impart neuroprotective effects against PD. 
Keywords: Mucuna pruriens; levodopa; Parkinson’s disease; neuroprotection; 
Caenorhabditis elegans; Drosophila melanogaster 
 
 20 
 
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease that leads 
to impaired motor function and is characterized by a loss of dopaminergic neurons in 
the substantia nigra and is second only to Alzheimer’s disease in its prevalence [1]. 
The etiology and pathophysiology of PD are not very well understood and have 
consequently stifled the development of effective therapeutic interventions for PD. 
Accumulating evidence suggests that elevated oxidative stress and 
neuroinflammation associated with microgliosis and intracellular aggregation of α-
synuclein molecules may be responsible for dopaminergic neuronal atrophy and 
ultimately the clinical manifestation of PD [2–4]. 
Mucuna pruriens, commonly known as Mucuna or velvet bean, is native to 
eastern India and western regions of China. Mucuna seeds, a rich source of naturally 
occurring levodopa (L-dopa; 4–7% in Mucuna seeds) [5], have been used traditionally 
as an effective remedy for several brain related maladies, including reducing tremors 
(as seen in PD), as documented in the ancient treatise of Ayurveda, the Indian 
traditional system of medicine [6]. The lack of effective pharmaceutical treatments has 
stimulated research interest in Mucuna as a PD therapeutic agent in several animal 
studies and a limited number of human clinical trials [7–9]. For example, Mucuna, at a 
dosage of 17.5 mg/kg, improved motor function and reduced dyskinesia in patients 
with advanced PD with fewer adverse effects as compared with the conventional 
treatment of L-dopa paired with a dopamine decarboxylase inhibitor, namely 
Carbidopa [9]. Mucuna has also been reported to show protective effects against PD 
in rodent models by increasing the activity of brain mitochondrial complex-I [10] and 
reducing motor dysfunction [11,12]. While several studies have attributed the anti-PD 
activities to naturally occurring high levels of L-dopa in Mucuna, emerging evidence 
suggests that other bioactive compounds besides L-dopa may also have 
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neuroprotective effects. For example, a Mucuna methanolic extract (0.1% dosage) 
containing low levels of L-dopa (0.01%) showed anti-PD effects including 
improvements of motor function and olfactory response in a Drosophila melanogaster 
genetic model of PD [13]. The anti-PD effects of the Mucuna methanolic extract were 
superior to that of the treatment of L-dopa (0.01%) alone in the aforementioned D. 
melanogaster model, suggesting that the overall anti-PD effects of Mucuna were a 
result of other compounds beyond L-dopa alone [13]. 
Our group has previously reported on the development of a neuroprotective 
potential algorithm for several Ayurvedic botanical extracts, among which M. pruriens 
ranked in the top four [14]. Given our group’s research interest in this medicinal plant, 
and to explore the role of its ‘non-L-dopa’ bioactives against PD, we prepared a M. 
pruriens seed extract (MPE) containing low amounts of L-dopa (<0.1%) with the 
following objectives: (1) to evaluate the antioxidant and anti-inflammatory effects of 
MPE in murine microglia (BV-2) and human neuroblastoma (SH-SY5Y) cells; (2) to 
assess the neuroprotective effects of MPE against neurotoxin-induced cytotoxicity in 
cellular PD models; and (3) to evaluate the neuroprotective effects of MPE using 
Caenorhabditis elegans and D. melanogaster models of chemically induced PD. 
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Materials and Methods 
Chemicals 
Dimethylsulfoxide (DMSO), levodopa (L-dopa), Resveratrol (Resv), 
lipopolysaccharide (LPS), 2',7'-dichlorofluorescin diacetate (DCF-DA), hydrogen 
peroxide (H2O2), 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenylpyridinium (MPP+), 
and rotenone were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). Dulbecco’s modified Eagle’s medium (DMEM) /F-12, phenol red-free DMEM 
medium and trypsin-versene were purchased from Life Technologies (Grand Island, 
NY, USA). 
Preparation of Mucuna pruriens Seeds Extract (MPE) 
Mucuna pruriens seeds (3–7% L-dopa) were botanically authenticated and 
generously provided by Verdure Sciences (Noblesville, IN, USA). Mucuna pruriens 
seeds were authenticated by Dr V. Singh (Pharmanza, Gujarat, India) with voucher 
specimen (No. PHPL/HB/013) deposited in the Heber-Youngken Garden and 
Greenhouse at the College of Pharmacy, the University of Rhode Island, RI, USA. 
Briefly, the ground M. pruriens seeds (150 g) were extracted with sonication in 
methanol (1000 mL) in an ultrasonic bath (Bransonic 8510; Branson Ultrasonics 
Corp. Danbury, CT, USA) for 0.5 h and macerated in methanol at room temperature 
for 24 h to afford a crude methanol extract (6.5 g), which was dried in vacuo (in a 
water bath at 35 °C); reconstituted in water; and then partitioned sequentially in n-
hexanes, ethyl acetate, and butanol with details as follows. The dried crude extract 
(6.5 g) was reconstituted in distilled water (250 mL) and sequentially partitioned with 
n-hexanes, ethyl acetate, and butanol (250 mL × 3 for each solvent). Each of these 
fractions, namely, hexanes (0.2 g), ethyl acetate (0.3 g), butanol (2.9 g), and the 
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remaining water portion (3.0 g), were dried in vacuo (in a water bath at 35 °C) to 
afford respective extracts. The levels of L-dopa were quantified in each dried extract 
(described below) and the extract with the lowest level of L-dopa, namely, MPE (the 
M. pruriens ethyl acetate extract; see Table 1), was selected for further biological 
evaluation. 
Quantification of L-dopa by Liquid Chromatography Electrospray Ionization Tandem 
Mass Spectrometry (LC-ESI-MS/MS) 
L-dopa was quantified by liquid chromatography electrospray ionization tandem 
mass spectrometry (LC-ESI–MS/MS) using methods and parameters published by 
our group and others with some modifications [15–19]. L-dopa quantifications were 
performed on a prominence ultra-fast liquid chromatography (UFLC) system 
(Shimadzu, Marlborough, MA, USA) coupled with a QTRAP 4500 system (Applied 
Biosystems/MDS Sciex, Framingham, MA, USA) with data acquired using Analyst 
1.6.3 software and processed using MultiQuant 3.0.1 software (Sciex, Framingham, 
MA, USA). The UFLC system consisted of three LC-20AD pumps, a DGU-20A 
degassing unit, SIL-20AC auto sampler, CTO-20AC column oven, and CBM-20A 
communication bus module. Chromatographic separation was performed using a 100 
mm × 4.6 mm i.d., 5 μm, XBridge C18 column (Waters, Milford, MA, USA). The 
mobile phase consisted of A (water containing 0.1% (v/v) formic acid) and B 
(methanol containing 0.1% (v/v) formic acid) with a gradient elution of 1% B from 0 to 
10 min, and 1−4% B from 10 to 20 min. The flow rate was 0.5 mL/min and the 
injection volume was 10 μL. The column temperature was maintained at 40 °C. The 
MS operated in electrospray ionization (ESI) in positive mode with multiple reaction 
monitoring (MRM). Nitrogen was used as the source gas in all cases. Parameters 
were optimized as follows: IonSpray voltage, 4500 V; nebulizer gas, 40 psi; auxiliary 
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heater gas, 45 psi; curtain gas, 20 psi; turbo gas temperature, 300 °C. Using an 
authentic L-dopa standard (purchased from Sigma-Aldrich Chemical Co.; St. Louis, 
MO, USA), L-dopa was analyzed by the multiple reaction monitor (MRM) mode using 
ion transition at m/z values of 198/152. All of the analyses of the standard and 
extracts were performed in triplicates (see LC-ESI-MS/MS spectra in the 
Supplementary Materials; Figure S1). The calibration curve (y = 5006.29x – 
13189.13; R = 0.99825) was acquired by plotting the peak area against the nominal 
concentrations of L-dopa. The linearity was in the range of 10–1000 ng/mL. The 
presence of L-dopa in Mucuna extracts was identified as a peak with a retention time 
of 3.95 min under the ion transition 198/152. The percentage of L-dopa in the 
different Mucuna extracts was calculated as follows: (ng/mL of L-dopa in 
extract)/(µg/mL of extract injected) × 100%. 
Cell Culture 
Murine microglia (BV-2) cells were kindly provided by Dr. Grace Y. Sun 
(University of Missouri at Columbia, MO, USA) and human neuroblastoma (SH-SY5Y) 
cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, 
USA). Cells were maintained at 37 °C in 5% CO2 with high glucose (4.5 g/L) 
DMEM/F-12 accompanied with 10% heat inactivated fetal bovine serum, and 1% P/S 
(100 U/mL penicillin, 100 mg/mL streptomycin) (Life Technologies, Gaithersburg, MD, 
USA). MPE was dissolved in distilled water to obtain a 10 mg/mL stock solution and 
further diluted in serum free media for treatments. Resv (used as a positive control for 
the cellular based assays) was dissolved in DMSO (10 mM) and diluted in media to 
the desired concentration. Control cells were treated with 0.1% DMSO in serum free 
media. 
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Cell Viability 
BV-2 and SH-SY5Y cells were seeded in white walled 96-well plates at 1 × 105 
cells/mL in serum free media. MPE (12.5, 25, and 50 μg/mL) were evaluated for 
cytotoxicity effects in BV-2 and SH-SY5Y cells. After 24 h, cell viability was 
determined using Cell Titer Glo 2.0 (CTG; Promega, Madison, WI, USA) according to 
methods previously reported by our group [14,20]. MPE was then evaluated for its 
cellular protective effects against several oxidative insults as follows. Cells were 
pretreated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% 
DMSO) for either 1 h (in BV-2 cells) or 2 h (in SH-SY5Y cells). Cellular oxidative 
stress was induced in BV-2 and SH-SY5Y with H2O2 (100 μM), SH-SY5Y with 6-
OHDA (25 μM), and MPP+ (2 mM). Cellular viability of BV-2 and SH-SY5Y cells after 
treatment were determined at 6 and 24 h, respectively, by the aforementioned CTG 
assay. 
Determination of Hydrogen Peroxide (H2O2)-Induced Reactive Oxygen Species 
(ROS) in Murine Microglia BV-2 Cells 
The production of H2O2-induced reactive oxygen species (ROS) in BV-2 cells 
was determined by a fluorescent probe (DCF-DA) using previously reported method 
with modifications [22]. BV-2 microglial cells were seeded in a black 96-well plate at 1 
× 105 cells/mL in serum free media. Cells were allowed to attach for 24 h and 
pretreated with MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% 
DMSO) for 1 h. Next, DCF-DA (20 μM) was added to each well and incubated for 25 
min. Cells were then washed with PBS and incubated with H2O2 (100 μM) for 6 h. The 
fluorescence signal of each cell was measured at excitation and emission 
wavelengths of 495 nm and 529 nm, respectively, using a SpectraMax M2 plate 
reader (Molecular Devices, Sunnyvale, CA, USA). 
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Measurement of Lipopolysaccharide (LPS)-Induced Nitric Oxide Species (NOS) in 
Murine Microglia BV-2 Cells 
The production of total nitric oxide species (NOS) was determined using the 
Griess reagent as previously reported by our group [14,20]. BV-2 cells were seeded 
in clear 24-well plates at 1 × 105 cells/mL in serum free media. Cells were treated with 
MPE (12.5, 25, and 50 μg/mL), Resv (20 μM), or solvent control (0.1% DMSO) for 1 
h. The cells were exposed to inflammatory stress induced by treating with LPS (1 
μg/mL) for 24 h. Next, culture media from each well were transferred to a 96-well 
plate and measured for total NOS using the Griess reagent kit (Promega, Fitchburg, 
WI, USA). Absorbance values were recorded using the SpectraMax M2 plate reader 
(Molecular Devices, Sunnyvale, CA, USA) at 535 nm. 
Non-Contact Co-Culture Assay with BV-2 and SH-SY5Y Cells 
The non-contact co-culture assay was performed according to protocols 
previously reported by our group [21]. Briefly, SH-SY5Y cells were seeded in white 
wall and clear bottom 96-well plates and allowed to adhere for 24 h. BV-2 cells were 
plated in 24 well plates and treated with MPE (12.5, 25, and 50 μg/mL), Resv (20 
μM), or solvent control (0.1% DMSO), followed by LPS (1 μg/mL) treatment for 24 h. 
Media from each treatment was collected and centrifuged at 15,000 rpm for 10 min. 
After centrifugation, BV-2 cell supernatant was used to treat SH-SY5Y cells for 24 h. 
Cellular viability of SH-SY5Y cells was determined using the CTG assay. 
1-Methyl-4-Phenylpyridinium (MPP+) Induced Dopaminergic Neurotoxicity in C. 
elegans 
Wild type C. elegans (N2) were maintained on nematode growth media culture 
plates at 20 °C and age synchronized as previously reported by our group [21]. Then, 
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40 μL of age synchronized L1 worms washed in S-complete were transferred to a 96-
well microplate (approximately 20 worms/well) with Escherichia coli OP50 (5 mg/mL), 
MPP+ (750 μM), and MPE (20 or 40 μg/mL) to a final volume of 50 μL. S-complete 
media was used for control groups. Live worms were counted every 12 h post 
treatment until no live worms remained. 
D. melanogaster Strains and Maintenance 
Wild type STR-5 flies were obtained from the Bloomington Stock Center 
(Department of Biology, Indiana University, Bloomington, IN, USA). Strains were 
reared on Formula 4-24® Instant Drosophila Medium (Carolina Biological Supply, 
Burlington, NC, USA) and reared on Bloomington Formulation (Genesee Scientific, 
San Diego, CA, USA) at 25 °C with 75% humidity and a 12-hour light/dark cycle [23]. 
Approximately 40–50 mating pairs were transferred into flasks and allowed to lay 
eggs. After nine days, newly eclosed male flies were collected over a period of three 
days and used in further experiments. 
Negative Geotaxis (Climbing) Assay in D. melanogaster 
Newly eclosed wild type (STR-5) male flies were randomly separated into 10 
groups of 50 flies each and transferred to control flasks (media only) or in treatment 
flasks (media + 40 μg/mL MPE). To induce neurotoxicity, every four days, flies were 
starved in empty vials for 24 h and transferred into vials containing a filter paper 
saturated with 1 mL of 10% sucrose (blank), 6-OHDA (1 mM), or rotenone (500 μM). 
After 24 h, the flies were transferred into vials with a fresh supply of their respective 
diets and used for climbing assay on day 10 post-eclosion. Flies from control and 
treatment groups were then tapped into the bottom of graduated cylinder (diameter: 
2.7 cm, height: 25 cm) superimposed with a ruler and allowed to climb for 10 s. Flies 
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were photographed (Canon, Inc,  Tokyo, JP, EOS 50D; 15.1 MP Digital SLR) at t0 and 
t10 seconds to calculate the climbing distance [24]. 
Statistical Analyses 
All data are presented as mean ± standard errors of three separate biological 
samples. Analyses of cellular data were conducted by analysis of variance (ANOVA) 
followed by Dunnett’s test for multiple comparisons of group means. The Kaplan–
Meier method was used to compare the survival curves of C. elegans and the survival 
differences were tested for statistical significance using the log rank test (Mantel 
Cox). For the D. melanogaster climbing assay, Welch’s t-test was used to compare 
the different treatment groups and generate p values (alpha = 0.05). Significance 
compared with control group is presented as p ≤ 0.05 (#), p ≤ 0.001 (###), and p ≤ 
0.0001 (####). Significance for all tests compared with toxic treatment was defined as 
follows: p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****). GraphPad 
Prism software 6.0 (GraphPad Software, Inc., San Diego, CA, USA) was used to 
calculate statistics for both the in vitro and in vivo analyses. 
 29 
 
Results and Discussion 
Preparation of Levodopa (L-dopa)-Reduced Mucuna pruriens Extract (MPE) 
Mucuna pruriens is a medicinal plant that is well known to naturally contain L-
dopa (4–7%) [5], which might be attributed to its neuroprotective effects against PD 
[6]. However, the presence of other phytochemicals in M. pruriens, including 
polyphenols (tannins, flavonoids, gallic acid, phenolic acids), saponins, terpenoids, 
alkaloids, and fatty acids, have been reported with various pharmacological activities 
(see Supplementary Materials; Figure S2 and Table S1) [6,25–29]. Recent studies 
also suggest that phytochemicals apart from L-dopa may also contribute to the overall 
neuroprotective activities of M. pruriens [13,30]. Therefore, in this study, we prepared 
a M. pruriens seed extract (MPE) containing reduced L-dopa levels (<0.1%), which 
was subsequently evaluated for its neuroprotective effects using a panel of in vitro 
and in vivo assays. The seeds of M. pruriens were extracted/solvent-solvent 
partitioned in varying solvents to yield extracts, which were evaluated for L-dopa 
content by liquid chromatography electrospray ionization tandem mass spectrometry 
(LC-ESI–MS/MS). As shown in Table 1, the L-dopa levels in the initial methanol M. 
pruriens seeds extract was 28.0%, which was significantly reduced to 0.03% in the 
ethyl acetate M. pruriens extract (MPE). As even this low level (0.03%) of L-dopa 
could impart biological effects, we evaluated a pure L-dopa solution (<0.1%) in 
several of the in vitro assays. Our preliminary data showed that the MPE, but not this 
pure L-dopa was active in these assays (data shown in Supplementary Materials 
Figures S5 and S6). Therefore, this MPE extract was selected for further evaluation of 
its neuroprotective effects in a panel of cell-based and in vivo bioassays as described 
below. 
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MPE Reduces Hydrogen Peroxide (H2O2)-Induced Toxicity and Reactive Oxygen 
Species (ROS) Production in Microglia BV-2 Cells 
Microglia are the native immune cells of the central nervous system (CNS) that 
undergo activation and proliferation to carry out phagocytosis, release inflammatory 
cytokines, and produce ROS and reactive nitrogen species (RNS) in response to 
injury and/or infection. Unresolved inflammation and excessive oxidant production by 
microglia are lethal to both neuronal and non-neuronal cells in the CNS and have 
been associated with PD. All of the Mucuna extracts including the crude methanol, 
hexanes, ethyl acetate (MPE), butanol, and water extracts (at 25 µg/mL) were 
evaluated for their protective effects against H2O2-induced toxicity in BV-2 cells. Our 
data showed that among the extracts, only the MPE significantly increased the 
viability of BV-2 cells exposed to H2O2 (see Supplementary Materials Figure S3A). 
Therefore, we evaluated the effects of MPE on oxidative stress induced by H2O2 in 
microglia BV-2 cells. MPE (12.5, 25, and 50 μg/mL) was non-toxic to BV-2 cells with 
cell viability greater than 90.3% at 24 h (Figure 1A). As shown in Figure 1B, the cell 
viability of H2O2-treated BV-2 cells decreased by 39.2%, as compared with the control 
group. Although MPE, at concentrations of 12.5, 25, and 50 μg/mL, showed a trend to 
ameliorate the H2O2-induced cytotoxicity in BV-2 cells, only MPE at a concentration of 
25 μg/mL significantly increased the cell viability of H2O2-treated BV-2 cells, by 
18.6%. The protective effects of MPE against the production of ROS by H2O2 in BV-2 
cells were then evaluated. As shown in Figure 1C, the production of ROS in H2O2-
treated BV-2 cells was elevated by 3.29-fold as compared with the control cells. MPE 
(12.5, 25, and 50 μg/mL) reduced the H2O2-induced production of ROS by 35.5, 29.1, 
and 61.6%, respectively, compared with the H2O2-treated BV-2 cells. Resveratrol 
(Resv; 20 μM), used as the positive control, reduced the H2O2-induced production of 
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ROS by 44.52%. These results are in agreement with our previous observation, 
wherein an M. pruriens water extract increased viabilities of murine BV-2 microglia 
and differentiated human SH-SY5Y neuronal cells that exposed to H2O2 [14]. 
Moreover, studies from other research groups also reported that Mucuna seeds 
powder (300 mg/kg/BW in diet) reduced oxidative stress in rodent sperm cells [31].  
MPE Reduces Lipopolysaccharide (LPS)-Induced Nitric Oxide Species (NOS) 
Production in Microglia BV-2 Cells and Protects SH-SY5Y Cells in a Co-Culture 
Model  
Elevated production of NOS leading to massive neuronal death has been 
implicated in PD [32]. All of the aforementioned Mucuna extracts (at 25 µg/mL) were 
evaluated for their protective effects against LPS-induced NO production in BV-2 
cells. Among the extracts, MPE showed the highest ability to reduce NO production in 
BV-2 cells exposed to LPS (see Supplementary Materials Figure S3B). Therefore, 
MPE was evaluated for its protective effects against neuroinflammation induced by 
LPS in BV-2 cells and in a non-contact co-culture model with SH-SY5Y 
neuroblastoma cells [21]. As shown in Figure 2A, LPS increased the NOS production 
in BV-2 cells by 4.46-fold as compared with the control group (control 8.987 μM vs. 
LPS 40.06 μM). MPE (12.5, 25, and 50 μg/mL) reduced the NOS production in LPS-
stimulated BV-2 cells by 8.9, 37.8, and 60.1%, respectively, as compared with the 
cells treated with LPS alone. Resv (positive control; 20 μM), also reduced the NOS 
production by 43.2% in the LPS-treated BV-2 cells and was similar to our previous 
observation [21]. In the non-contact co-culture model (Figure 2B), conditioned media 
collected from BV-2 cells treated with LPS alone reduced the cell viability of SH-SY5Y 
cells by 43.1%. The conditioned media from treatment of LPS and MPE (12.5, 25 and 
50 μg/mL) significantly increased the cellular viability of SH-SY5Y cells by 19.4, 
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23.2%, and 40.1%, respectively, as compared with the cells treated with media from 
LPS-treated BV-2 cells. The positive control, Resv (20 μM), also increased the cell 
viability of SH-SY5Y cells by 29.3%. Our results support other studies on Mucuna 
reporting a reduction in nitrite levels induced by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in the nigrostriatal region of Parkinsonian mice brain [33].  
MPE Reduces Oxidative Stress Induced Cytotoxicity in SH-SY5Y Cells 
Several neurotoxins, including 6-OHDA and MPP, induce oxidative cytotoxicity in 
dopaminergic neurons by multiple mechanisms and thus are used to model PD 
[2,34,35]. The protective effects of MPE were evaluated in SH-SY5Y neuroblastoma 
cells against oxidative stress induced neurotoxicity. MPE (12.5, 25, and 50 μg/mL) did 
not induce cytotoxicity of SH-SY5Y cells after 24 h incubation (viability >90%) in the 
CTG assay (Figure 3A). Toxicity was induced in SH-SY5Y neuroblastoma by 
treatment with 6-OHDA, H2O2, and MPP+ (25 μM, 100 μM, and 2 mM, respectively). 
Treatment of 6-OHDA significantly reduced the viability of SH-SY5Y cells by 71.9% 
as compared with the control group, while MPE (12.5, 25, and 50 μg/mL) reduced 6-
OHDA-induced cell death of SH-SY5Y cells by increasing cell viability compared with 
the 6-OHDA treated group by 11.9%, 38.5%, and 23.9%, respectively (Figure 3B). 
Treatment of H2O2 reduced SH-SY5Y cells viability by 65.1% as compared with 
control, while MPE (at higher concentrations of 25 and 50 μg/mL) showed moderate 
protective effects by increasing SH-SY5Y cell viability compared with cell viability of 
the H2O2 treated group by 19.5% and 16.3%, respectively (Figure 3C). MPP+ 
treatment significantly reduced the viability of SH-SY5Y cells by 46.7% as compared 
with control (Figure 3D); however, MPE showed no protective effects. Our findings 
obtained from these cellular PD models are in agreement with previously reported 
neuroprotective effects of Mucuna in neurotoxins-induced PD animal models. For 
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example, Mucuna treatment reduced 6-OHDA-induced L-dopa depletion in 
nigrostriatal tract of rats with PD symptoms [10,33].  
MPE Reduces Lethality of MPP+ Induced Dopaminergic Neurotoxicity in C. elegans 
The neurotoxin, MPTP, is metabolized to MPP+ by monoamine oxidase-B and is 
subsequently taken up by dopaminergic neurons, where it inhibits mitochondrial 
complex I, resulting in ATP depletion to induce neuronal death [35]. Therefore, we 
evaluated the effects of MPE against MPP+ dopaminergic neurotoxicity in wild type C. 
elegans. The effects of MPE in MPP+ induced neurotoxic paralysis and lethality in C. 
elegans were evaluated at concentrations of 20 and 40 μg/mL (IC10 = 42.1 μg/mL). 
The median and maximum survival of worms after exposure to 750 μM MPP+ was 72 
h (Table 2). 
Treatment of MPP+ significantly reduced the median and maximum survival by 
3.2-fold (72 h) and 3.5-fold (72 h), respectively, compared with worms in the control 
group (Figure 4A). MPE at 20 μg/mL significantly increased (p < 0.001) the median 
and maximum survival by 1.3-fold (96 h) and 1.9-fold (138 h), respectively, compared 
with worms treated with MPP+ alone (Figure 4B). MPE at 40 μg/mL significantly 
increased the mean and maximum survival in C. elegans by 1.8-fold (132 h) and 
2.25-fold (162 h) respectively, compared with worms treated with MPP+ alone (Figure 
4C and Table 2). 
MPE Abrogates Chemically Induced Neurotoxicity in D. melanogaster  
Changes in several behavioral phenotypes of D. melanogaster in response to 
genetically or chemically induced neurotoxicity have been exploited extensively to 
evaluate potential neuroprotective effects of therapeutics [36]. As MPE was 
significantly more neuroprotective at 40 μg/mL in reducing MPP+ induced 
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dopaminergic neurotoxicity in C. elegans (Figure 4), we used this dosage to 
determine its effect on climbing behavior (negative geotaxis) in D. melanogaster 
neurotoxin induced PD model. The two neurotoxins (6-OHDA and rotenone) used in 
our study induce a PD-like phenotype in D. melanogaster characterized by several 
behavioral changes including a muted innate negative geotaxis response due to 
locomotor defects. The aforementioned toxins generally injure dopamine neurons and 
cause behavioral defects including climbing, which can be measured by negative 
geotaxis assay. Similar to MPP+, rotenone is another mitochondrial complex I inhibitor 
that causes ATP impairment and ROS production and induces neuronal death [35]. In 
our study, D. melanogaster were exposed to 6-OHDA and rotenone to induce PD like 
phenotype. After 10 days, flies exposed to neurotoxins showed a highly muted 
climbing ability compared with control group. This loss of negative geotaxis ability was 
significantly ameliorated when flies were pre-treated with MPE. 
The median climbing distance in 6-OHDA treated flies and rotenone treated flies 
was 18.6% (8.7 cm; p ≤ 0.05) and 37.8 % (6.2 cm, p ≤ 0.001) lower than in control 
flies (10.95 cm), respectively (Figure 5). Treatment of MPE alone significantly 
increased the climbing distance in flies by 42.5% (15.9 cm) compared with the control 
group (Figure 5). Pre-treatment with MPE abrogated the effect of neurotoxins on 
climbing behavior. In the MPE + 6-OHDA treated flies, the median climbing distance 
was 54.5% (13.95 cm) higher as compared with flies that were treated with 6-OHDA 
alone (Figure 5). In the MPE + rotenone treated flies, this was 48.7% (9.9 cm) higher 
than in flies that were exposed to rotenone only without any MPE pre-treatment 
(Figure 5). Our results on the neuroprotective effects of MPE on neurotoxin induced 
PD models using C. elegans and D. melanogaster support previous studies with 
Mucuna in rodent models of PD using MPTP [33] and 6-OHDA [25] and provide 
further evidence on the neuroprotective effects of non-L-dopa bioactives in MPE. 
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Conclusions 
In summary, we developed a L-dopa reduced Mucuna pruriens extract (MPE) 
and evaluated its neuroprotective effects in murine microglia BV-2 and 
neuroblastoma SH-SY5Y cells. MPE treatment decreased BV-2 and SH-SY5Y 
cytotoxicity induced by oxidative stress and inflammation. In addition, MPE 
ameliorated dopaminergic neurotoxin-induced lethality in SH-SY5Y (6-OHDA), C. 
elegans, and recovered climbing ability D. melanogaster models for PD. Taken the 
data from the in vitro and in vivo experiments together, MPE showed neuroprotective 
effects in our PD models. Studies on the anti-PD effects of purified compounds 
isolated from MPE and their potential mechanism/s of action will be pursued by our 
group in the future. 
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Table 1. Levodopa (L-dopa) content for each Mucuna pruriens seed extracts as 
determined by liquid chromatography electrospray ionization tandem mass 
spectrometry (LC-ESI-MS/MS). 
 
Extract Yield (%; w/w) L-dopa Content (%; w/w) 
methanol 100 28.0 
hexanes 3.1 0.54 
ethyl acetate 4.7 0.03 
butanol 45.3 10.05 
water 46.9 21.39 
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Figure 1. Effects of Mucuna Pruriens Seeds Extract (MPE) (12.5, 25, 50 
μg/mL) on cellular viability and reactive oxygen species (ROS) levels in BV-2 
cells. Effects on BV-2 cellular viability by MPE alone (A); by MPE after H2O2-
induced BV-2 cell toxicity (B); and on ROS levels after BV-2 cell exposure to 
H2O2 (C). All data expressed as mean ± standard error (n = 3), significance 
was reported by analysis of variance (ANOVA) followed with Dunnett 
multiple comparison testing, as compared with control p ≤ 0.001 (###), and p 
≤ 0.0001 (####); as compared with toxic agent, p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 
0.001 (***), and p ≤ 0.0001 (****). Resv—Resveratrol. 
 
 
 39 
 
 
Figure 2. Effects of MPE (12.5, 25, 50 μg/mL) on production of nitric oxide in 
BV-2 microglia and resulting influence in non-contact co-culture in SH-SY5Y 
neuroblastoma. Effects on levels of nitric oxide produced in BV-2 induced 
with lipopolysaccharide (LPS) (A), and on SH-SY5Y cell viability after co-
culture with BV-2 LPS-induced media (B). All data expressed as mean ± 
standard error (n = 3), significance was reported by ANOVA followed with 
Dunnett multiple comparison testing, as compared with control p ≤ 0.0001 
(####); as compared with toxic agent, p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 
0.0001 (****). 
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Figure 3. Effects of MPE (12.5, 25, and 50 μg/mL) on cellular viability of SH-
SY5Y human neuroblastoma cells against toxic models of Parkinson’s 
disease. Effects of MPE (12.5, 25, and 50 μg/mL) alone on SH-SY5Y cell 
viability (A), of MPE after 6-OHDA-induced toxicity (B), of MPE against 
H2O2-induced toxicity (C), and of MPE against MPP+ induced toxicity (D). 
Data shown as mean ± standard error (n = 3), significance was reported by 
ANOVA and subsequent Dunnett multiple as compared with control p ≤ 
0.001 (###), and p ≤ 0.0001 (####); as compared with toxic agent, p ≤ 0.05 
(*), and p ≤ 0.01 (**). 
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Table 2. Survival (median and maximum) of C. elegans (N2), as compared 
with 1-methyl-4-phenylpyridinium (MPP+) treatment (750 μM). MPE 
treatment at both 20 and 40 μg/mL significantly increased survival, as 
determined by log rank test (Mantel Cox), n > 100, p ≤ 0.05 (*), p ≤ 0.001 
(***). 
 
Survival (h) MPP+ MPP
+ + MPE 
(20 μg/mL) 
MPP+ + MPE 
(40 μg/mL) 
Median 72 96 * 138 *** 
Maximum 72 132 * 162 *** 
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Figure 4. Effects of MPE (20 and 40 μg/mL) on lifespan of C. elegans after 
MPP+ exposure. MPP+ at concentration of 750 μM reduces C. elegans 
lifespan, as compared with control group (A). MPE at concentrations 20 
μg/mL (B) and 40 μg/mL (C) increase C. elegans lifespan, as compared with 
toxic MPP+ exposure (750 μM). Survival curves of C. elegans were 
statistically analyzed by log rank test (Mantel Cox), as compared with MPP+ 
treatment (n > 100). 
 
 43 
 
 
Figure 5. Effects of MPE on negative geotaxis in Drosophila melanogaster. 
Effects of MPE (40 μg/mL) alone on climbing ability, by MPE after 6-OHDA 
(1 mM) exposure, and on MPE climbing ability after rotenone exposure (500 
μM). Significance was determined as compared with control and p ≤ 0.05 (#) 
and p ≤ 0.0001 (####); compared with toxic treatment using Welch’s t-test 
with three replicates o f n > 40, p ≤ 0.0001 (****). 
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Abstract 
 
Mucuna pruriens, known to naturally contain levodopa, is used as a traditional 
medicine in Ayurveda to treat symptoms of Parkinson’s disease (PD). Our group has 
previously reported that a levodopa-reduced M. pruriens ethyl acetate (MPEA) seed 
extract showed neuroprotective effects against PD in several in vitro and in vivo 
models but its chemical constituents remain unknown. Herein, a phytochemical 
investigation of MPEA led to the isolation and identification of phaseic acid (1), cis- 
and trans-dihydrophaseic acid (2 and 3), gancidin W (4), maculosin (5), levodopa (6), 
2,6-dihydroxybenzoic acid (7), and protocatechuic acid (8). All of the compounds, 
apart from levodopa, are being reported from Mucuna pruriens for the first time.  
Compounds 3-8 were evaluated for their neuroprotective effects in human SH-SY5Y 
neuroblastoma cells. 
 
Keywords:  Mucuna pruriens, Parkinson’s disease, neuroprotection, levodopa 
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Body 
 
Mucuna pruriens L., belonging to the family Fabaceae, and commonly known 
as Mucuna or velvet bean, is a medicinal plant which naturally contains levodopa  [1].  
The seeds of this medicinal plant have been used traditionally to treat brain disorders 
associated with Parkinson’s disease (PD) in the Indian traditional system of medicine, 
Ayurveda. Although levodopa is believed to be the major constituent in Mucuna 
responsible for its neuroprotective effects against PD symptoms [1,2],  increasing 
evidence suggests that other phytochemicals may also contribute to the anti-PD 
effects of this natural product [3–5]. 
Our group has previously reported that a levodopa-reduced M. pruriens ethyl 
acetate (MPEA) seeds extract showed neuroprotective effects against PD in several 
in vitro and in vivo models including murine BV-2 microglia and human SH-SY5Y 
neuroblastoma cells, Caenorhabditis elegans, and Drosophila melanogaster [6]. 
However, the phytochemical constituents of this MPEA remain unknown.  Herein, we 
report the isolation and identification of eight compounds from this MPEA including 
phaseic acid (1) [7], cis-dihydrophaseic acid (2) [7], trans-dihydrophaesic acid (3) [7], 
gancidin W (4)[8], maculosin (5) [9], levodopa (6) [10], 2,6-dihydroxybenzoic acid (7) 
[11], and protocatechuic acid (8) [11]. While levodopa (6) has been previously 
reported from Mucuna pruriens [12], this is the first report of the isolation and 
identification of compounds 1-5, 7, and 8 from M. pruriens.  
Due to limited quantities, only isolates 3-8 (at non-toxic concentrations of 10 
and 20 µM) were evaluated for their neuroprotective effects in human neuroblastoma 
SH-SY5Y cells. The SH-SY5Y cells were pretreated with compounds 3-8 for 1 h after 
which neurotoxicity was induced with known neurotoxic agents, 6-hydroxydopamine 
(6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+).  Although MPEA was previously 
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reported to show anti-PD effects in several in vitro and in vivo PD models [6], the 
purified isolates alone (at these test concentrations) were not effective in the SH-
SY5Y cells.  It is possible that the complex matrix of constituents present in toto in 
MPEA may exert their neuroprotective effects in an additive, synergistic and/or 
complementary manner. However, further studies would be required to confirm this 
which will be pursued by our group in the future.  In summary, the isolation and 
identification of eight phytochemicals from a M. pruriens ethyl acetate seeds extract 
are reported here. Also, this is the first report of compounds 1-5, 7, and 8 from M. 
pruriens.  
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Experimental 
General Experimental 
 
The 1H and 13C nuclear magnetic resonance spectroscopic experiments were 
conducted on a Varian 400 MHz instrument. Deuterated methanol (CD3OD) was used 
as solvent for the NMR experiments. Solvents were either ACS or HPLC grade 
purchased from Tansoole (Shanghai, China) or Sigma-Aldrich (St. Louis, MO, USA). 
Column chromatographic experiments were conducted on a C18 column with 
reverse-phased silica gel (12 nm, S-50 µm, YMC) and pre-coated silica gel GF254 
plates (Qingdao Marine Chemical Plant, Qingdao, People’s Republic of China).  
Plant Material 
 
Mucuna pruriens seeds were kindly provided by Verdure Sciences 
(Noblesville, IN, USA) and voucher specimen (No. PHPL/HB/013) are deposited in 
the Heber Youngken Herbarium and Greenhouse at the College of Pharmacy, the 
University of Rhode Island, RI, USA.  
Extraction and Isolation 
 
M. pruriens seeds were extracted with methanol to obtain a crude extract. The 
crude extract was suspended in distilled water and successively partitioned with 
petroleum ether, ethyl acetate, and n-butanol for 3 times to afford corresponding 
extract after solvent removal. The ethyl acetate extract was subjected to a silica gel 
column and eluted with dichloromethane and methanol (10:1, 8:1, 6:1, 4:1, 2:1, and 
1:1; v/v) to obtain 6 fractions (Fr 1-6). Fraction 1 was purified by LH20 column to 
afford 7 fractions. Fraction 1 was purified by a C18 ODS column chromatography to 
obtain sub-fractions (Fr 1A1-1A7).  Fraction 1A2 was further purified by reversed-
phase semi-preparative HPLC with MeOH/0.1 % aqueous TFA (40:60; v/v) to afford 
compounds 4 and 2 (Rt = 12 and 14 min, respectively). Fraction 3 was purified by 
semi-preparative HPLC with MeOH/0.1 % aqueous TFA (20:80 – 16:84; v/v) to afford 
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compound 5 (Rt = 14.3 min). Fraction 2 was separated by LH20 column to afford 8 
subfractions (Fr2A1-2A8). Fraction 2A2 was purified by HPLC with MeOH/0.1 % 
aqueous TFA (30:70 – 43:57; v/v) to obtain compounds 3 and 1 (Rt = 12.5 and 14.1 
min, respectively). Fraction 2A6 was purified by HPLC with MeOH/0.1 % aqueous 
TFA (11:89 – 37.8:62.2; v/v) to obtain compounds 6, 7, and 8 (Rt = 10.3, 15.5, and 
23.6 min, respectively). 
Cell Culture 
 
Human neuroblastoma (SH-SY5Y) cells were purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously 
described [6]. Compounds were dissolved in DMSO to achieve stock solutions (10 
mM) and were further diluted to desired concentrations in serum free media for cell 
treatments. Cell viability was evaluated after 24 h of treatment of test compounds 
using a Cell Titer Glo 2.0 (CTG; Promega, Madison, WI, USA) assay. The 
neuroprotective effects of selected test compounds (at 10 and 20 µM) were evaluated 
against neurotoxic agents including 6-hydroxydopamine (6-OHDA; 25 μM), and 1-
methyl-4-phenylpyridinium (MPP+; 2 mM) using a previously described method [6]. 
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Figure 1: Chemical structures of compounds 1-8 from Mucuna pruriens ethyl acetate 
(MPEA) seeds extract. 
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Figure 2: Evaluation of single isolated compounds in human neuroblastoma (SH-
SY5Y). Cell viability of each compound was assessed after 24h (A), exposure to 6-
OHDA (B) and exposure to MPP+ (C). All data expressed as mean ± standard error (n 
= 4), significance reported by analysis of variance (ANOVA) followed by Dunnett 
multiple comparison tests, as compared to toxic agent p £ 0.0001 (****). 
  
 59 
 
Table 1: NMR of Isolated compounds were compared to published literature to 
confirm structure and name of compounds.  
 
 
Compound 
Number 
Compound Name Publication 
1 Phaseic acid [7] 
2 Cis-dihydrophaseic acid [7] 
3 Trans-dihydrophaesic acid [7] 
4 Gancidin W [8] 
5 Maculosin [9] 
6 Levodopa [10] 
7 2,6-Dihydroxybenzoic acid [11] 
8 Protocatechuic acid [11] 
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Abstract 
Increasing evidence supports the beneficial effects of polyphenol-rich diets, 
including the traditional Mediterranean diet, for the management of cardiovascular 
disease, obesity and neurodegenerative diseases. However, a common concern 
when discussing the protective effects of polyphenol-rich diets against diseases is 
whether these compounds are present in systemic circulation in their intact/parent 
forms in order to exert their beneficial effects in vivo. Here, we explore two common 
classes of dietary polyphenols, namely isoflavones and lignans, and their gut 
microbial-derived metabolites for gut and blood–brain barrier predicted permeability, 
as well as protection against neuroinflammatory stimuli in murine BV-2 microglia. 
Polyphenol microbial metabolites (PMMs) generally showed greater permeability 
through artificial gut and blood–brain barriers compared to their parent compounds. 
The parent polyphenols and their corresponding PMMs were evaluated for 
protective effects against lipopolysaccharide-induced inflammation in BV-2 
microglia. The lignan-derived PMMs, equol and enterolactone, exhibited protective 
effects against nitric oxide production, as well as against pro-inflammatory cytokines 
(IL-6 and TNF-a) in BV-2 microglia. Therefore, PMMs may contribute, in large part, 
to the beneficial effects attributed to polyphenol-rich diets, further supporting the 
important role of gut microbiota in human health and disease prevention.  
Keywords: polyphenol; gut microbial metabolites; permeability; equol; enterodiol; 
enterolactone; inflammation  
 63 
 
Introduction 
In the United States, obesity is a growing epidemic. There have been many 
studies that link obesity to an increased risk of developing other diseases, such as 
cardiovascular disease, diabetes, and Alzheimer’s disease [1]. A quantitative 
systematic review estimated that the United States spent $113.9 billion dollars total, 
or 4.8% of all healthcare spending in 2008 on overweight and obesity care  [2]. The 
standard American diet consisting of high levels of saturated fat, sodium and sugars, 
contributes to these staggering obesity numbers [3]. People abiding by alternative 
diets in countries such as Greece and Italy exhibit decreased risks of obesity as well 
as confounding diseases such as metabolic syndrome [4]. 
Increasing evidence supports the beneficial effects of a traditional Mediterranean 
diet in the management of cardiovascular disease, obesity and most recently, 
neurodegenerative diseases [5]. The Mediterranean diet is characterized by high 
intake of polyphenols and unsaturated fats, with most of the beneficial effects from 
this diet being attributed to the high polyphenol intake [6,7]. There has been an 
increased interest in polyphenols for the treatment of neurodegenerative diseases as 
they exhibit the ability to cross the blood–brain barrier (BBB) and have a wide range 
of bioactive properties including antioxidant, anti-inflammatory, anti-apoptotic and 
lipid-lowering properties [8,9].  
Polyphenols are a large class of secondary metabolites produced via the 
shikimate-derived phenylpropanoid or polyketide pathways, and they are 
characterized by the presence of two or more benzene rings bearing hydroxyl 
group(s) and lack any nitrogenous functional group in their core structure [10]. 
Polyphenols are further divided into several subclasses including stilbenes, 
flavonoids, lignans, and phenolic acids [11]. Although polyphenols exhibit biological 
effects in a variety of assays, their poor bioavailability, extensive phase-2 metabolism, 
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and whether they achieve physiologically relevant concentrations as their 
intact/parent forms to exert their protective effects, have been questioned. Rather, a 
growing consensus is that dietary polyphenols are metabolized by microbiota in the 
colon to yield bioactive gut microbial metabolites [12–16]. Herein, two common 
classes of dietary polyphenols were investigated, isoflavones and lignans, as well as 
their known polyphenol microbial metabolites (PMMs). 
The isoflavones, genistein (GEN) and daidzein (DAI), are two soy-derived 
polyphenols that have been extensively studied for their bioactivities. Structurally 
similar to estrogen, isoflavones are comprised of a 3-phenylchromen-4-one 
backbone, modified by glycosides, O-substituents, and prenylated derivatives [17]. 
They exhibit the ability to serve as antioxidants, alleviate oxidative stress, and reduce 
the risk of hormone-dependent cancers [18–20]. GEN has been identified as a 
potential nutraceutical for Alzheimer’s disease as it exhibits the ability to inhibit 
mitochondria-dependent apoptosis, and alleviate b-amyloid neurotoxicity, providing 
neuroprotection [21–23]. DAI also shows pro-apoptotic and neurotoxic effects against 
glutamate treatment in mouse hippocampal and cerebral cell cultures [24]. When 
metabolized in the gut by intestinal microflora, these isoflavones are converted into 
equol (EQ) (Figure 1) [25]. EQ has exhibited bioactive properties in cardiovascular 
disease, bone health, and cancers [26]. A recent study identified EQ as protective 
against oxidative stress in microglia, through the downregulation of neuronal 
apoptosis, and increased neurite growth [14]. 
Lignans often have complex structures made up of C6 and C3 units [27]. In plant 
tissues, lignans are often found as dimers and can be in the free state or sugar bound 
[28]. Data suggests a lignan-rich diet has numerous benefits such as prevention of 
hormone-dependent tumors, decrease in plasma cholesterol and glucose profiles, 
and delaying type 2 diabetes [29–31]. The common and prototypical dietary lignan, 
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secoisolariciresinol (SECO), is known to be deglycosylated by bacteria and converted 
to the PMMs enterodiol (ED) and enterolactone (EL) (Figure 1) [32].  
A common question regarding dietary polyphenols is whether they are present in 
systemic circulation in physiologically relevant concentrations to exert their biological 
effects. Polyphenol concentrations in the blood generally range from 0.1–1.0 μM [33]. 
However, certain phenolic metabolites such as pyrogallol sulfate and catechol sulfate 
reached plasma concentrations ranging from 5–20 μM, while their parent compounds 
were undetected [34]. Absorption through the GI tract is complex as the pH changes 
as compounds traverse through the stomach to the intestines, which changes the 
bioavailability of substances [35]. The high-throughput parallel artificial membrane 
permeability assay (PAMPA) is used to determine permeability properties related to 
the transcellular in vivo absorption process of large compound libraries [36]. PAMPA 
has become a robust, versatile method for predicting passive permeability of 
compounds through the gastrointestinal (GI) track, the BBB, and skin [37,38]. A major 
concern for the development of pharmaceuticals for CNS-related diseases is the 
ability of compounds to cross the BBB, therefore it is of high importance to evaluate 
this ability early in drug discovery [39]. The BBB is a lining of endothelial cells that 
protects the brain from the peripheral nervous system [40]. PAMPA uses a 
combination of phospholipids specific to the membrane being tested along with a 
microfiber filter to simulate the biological membrane [41].  
Herein, we propose that certain PMMs derived from gut microflora metabolism of 
their parent polyphenols are gut and BBB permeable and may provide protection 
against neuroinflammatory stress. To explore this hypothesis, we first performed in 
silico screening for gut and BBB permeability and then PAMPA of the parent 
polyphenols and their respective PMMs. Neuroprotective activity for all of the 
compounds was then assessed by evaluating the levels of nitric oxide species (NOS) 
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and inflammatory cytokines against LPS-induced inflammation in BV-2 murine 
microglia. 
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Materials and Methods  
Compounds and Chemicals 
Dimethylsulfoxide (DMSO) and lipopolysaccharide (LPS) were purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Daidzein (DAI), (±) enterodiol (ED) 
(Cat# 45198-5MG-F), (±) enterolactone (EL) (Cat# 45199-1MG-F), genistein (GEN) 
and (±) secoisolariciresinol (SECO) (Cat# 60372-5MG-F) were purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). S-Equol was purchased from 
Chembest (Shanghai, China). Antipyrine, corticosterone, ketoprofen, ranitidine, 
theophylline and verapamil were purchased as PAMPA controls from Pion, Inc 
(Billerica, MA, USA).  
In Silico ADME Predictors 
 
The in silico tool SwissADME was used as a measure to predict BBB and gut 
permeability. Predicted permeability was assessed for each individual compound and 
control, as previously explained [56]. 
Parallel Artificial Membrane Permeability Assay (PAMPA)  
Parallel Artificial Membrane Permeability Assay was performed to analyze both 
blood–brain barrier (BBB) and gut passive permeability. All materials for PAMPA were 
purchased from Pion, Inc (Billerica, MA, USA). Both the gut and BBB assays were 
performed according to the manufacturer’s instructions. Briefly, test compounds and 
standards were prepared at 10 mM concentrations in DMSO. For the gut assay, 
Prisma HT buffer was adjusted to pHs 5, 6.2, and 7.4 by adding 0.5 M NaOH. In the 
deepwell plate provided by Pion, 1 mL of each pH-adjusted buffer was added to 
separate wells. For each pH, 5 µL of the sample was added to the 1 mL of buffer then 
mixed thoroughly with a pipette, diluting the sample to a final concentration of 50 µM. 
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Next, 200 µl of the diluted sample was added to the donor (bottom) plate from the 
Pion sandwich assay, 5 µL of GIT lipid matrix was added to the membrane on the 
bottom of the acceptor plate, and 200 µL of acceptor sink buffer was added in each 
well of the acceptor plate. The sandwich was assembled, and the plate incubated at 
room temperature for 4 h undisturbed. In BBB assays, compounds (10 mM) were 
diluted to final concentrations of 50 µM in Prisma HT Buffer (pH = 7.4). The PAMPA 
sandwich was created with the donor (bottom), BBB artificial membrane, and brain 
sink buffer as the acceptor (top). The assay was performed for 1 h at room 
temperature with shaking (60 µm) using the manufacturer-supplied GIT Box. After 
incubation, the UV profiles of the donor and acceptor plates were read on the 
SpectraMax plate reader connected to the PAMPA software. PAMPA software 
calculated the –log Pe values for each compound and standard using the UV profiles 
of the donor and acceptor plates. Standards were all within 0.25 units of the expected 
value provided by PAMPA and each sample was averaged with 4 replicates. 
Cell Culture Conditions  
Murine microglia (BV-2) were generously provided by Dr. Grace Sun of the 
University of Missouri at Columbia. Cells were maintained in DMEM/F12 (Life 
Technologies, Gaithersburg, MD, USA) supplemented with 10% (v/v) sterile filtered 
and heat inactivated Fetal Bovine Serum in addition to 1% (v/v) 
Penicillin/Streptomycin Antibiotic Solution (Life Technologies, Gaithersburg, MD, 
USA). Cells were incubated at approximately 65% relative humidity at 37 °C under 
atmospheric oxygen and 5% CO2. Cells were passaged using Trypsin-EDTA (Life 
Technologies, Gaithersburg, MD USA), enumerated, and checked for viability using 
Trypan blue (Sigma Aldrich, St. Louis, MO, USA) dye exclusion. DMSO (Sigma 
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Aldrich, St. Louis, MO, USA) was used to dissolve compounds and did not exceed 
0.1% when incubated with cells.  
Cell Viability 
The cytotoxicity of each compound was determined in BV-2. Briefly, cells were 
seeded in 96 white-walled, clear bottom plates at 100,000 cells/mL. Cells were 
allowed to adhere for 24 h. Compounds were prepared to 10 mM in DMSO, then 
diluted in serum-free media to yield concentrations of 20 and 10 μM. Cells were 
treated with prepared concentrations of each compound for 24 h. Cellular viability 
was determined as a percentage of control (DMSO) by Cell Titer Glo 2.0 (CTG; 
Promega, Madison, WI, USA), read for luminescence on the SpectraMax M2 plate 
reader (Molecular Devices, Sunnyvale, CA, USA). 
LPS Stimulation of Murine Microglia BV-2 Cells 
As previously published, BV-2 cells were seeded at a density of 100,000 cells/mL 
in 24-well plates [57]. After reaching a confluency of 85%, cells were exposed to 
either DMSO, SECO (10 μM), ED (10 μM), EL (10 μM), GEN (20, 10 μM), DAI (20, 10 
μM), or EQ (20, 10 μM), for 1 h prior to incubation of LPS (1 μg/mL) for 23 h. Media 
were collected, aliquoted for nitric oxide and cytokine analysis. 
Quantification of Nitric Oxide 
Nitric Oxide (NO) was detected in BV-2 culture media following the stimulation of 
LPS for 24 h from the previously described experiment by way of the Griess Assay 
(Promega, Madison WI), according to the manufacturer’s protocol. 
Measurement of IL-6 and TNF-α  
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IL-6 and TNF-α were measured from BV-2 media using Enzyme Linked 
Immunosorbent Assay (ELISA) provided by Biolegend (San Diego, CA, USA) [57]. 
Statistical Analysis 
All data are reported as mean ± standard errors of at least three independent 
biological samples. The analysis of all cellular data was conducted by ANOVA 
followed by Dunnett’s test or Tukey’s test for multiple comparisons of group means. 
The significance of the toxic agent compared to the control group is presented as p ≤ 
0.001 (###) and p ≤ 0.0001 (####). The significance for tests compared to toxic 
treatment was defined as: p ≤ 0.03 (*), p ≤ 0.002 (**), p≤0.0002 (***) and p ≤ 0.0001 
(****). GraphPad Prism software 7.0 (GraphPad Software, Inc., San Diego, CA, USA) 
was used for all statistical analysis calculations and graphical representations.  
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Results 
SwissADME Predicts Polyphenol Microbial Metabolites Are Highly Gut and BBB 
Permeable 
Utilizing SwissADME in silico modeling, BBB and gut permeability were predicted 
(Table 1). All six of the compounds (parent polyphenols and their corresponding 
PMMs; Figure 1) were identified as having high gut absorbance. The positive PAMPA 
gut controls, verapamil, ranitidine, ketoprofen and antipyrine, all exhibited high gut 
permeability in the SwissADME predictor. ED, DAI and EQ were predicted to have 
BBB permeability. The PAMPA BBB controls, both BBB permeable and impermeable, 
were additionally screened in SwissADME, predicting passive permeability for 
verapamil and corticosterone, but no BBB passive permeability by theophylline. After 
this predictive measure, compounds were experimentally evaluated for passive 
permeability in the gut and BBB. 
SECO, GEN, DAI, EL, and EQ Exhibit High Permeability through PAMPA Gut 
Compounds were evaluated for their permeability through simulation membranes 
of the gut using PAMPA at pHs 5.0, 6.2, and 7.4 (Figure 2). Verapamil was used as 
the highly permeable control, ranitidine as the low permeability, and antipyrine was 
used as an intermediate control. Ketoprofen was used as a pH-dependent control. At 
pH 5, EL showed the highest permeability with a -log Pe value of 4.27 ± 0.05, closely 
followed by EQ at 4.35 ± 0.11. At pH 6.2, EQ showed the highest permeability with a -
log Pe value of 4.20 ± 0.02 followed by EL at 4.37 ± 0.02. At pH 7.4, the same trend 
followed as pH 6.2. SECO showed moderate permeability at all pHs tested, and DAI 
was most permeable at pHs 5 and 6.2. Parent compounds showed high permeability 
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in all three pH treatments, while the metabolite ED showed the lowest permeability of 
all test compounds in all three pH treatments tested (Figure 2).  
GEN, EL, and EQ Show BBB Passive Permeability in PAMPA Assay 
Isoflavones and lignans were evaluated for BBB penetration through PAMPA 
experiments (Figure 3). Verapamil, corticosterone and theophylline were controls for 
high, intermediate and low permeability, respectively, and yielded similar permeability 
measures as previously reported [35,39]. EL and EQ exhibited high permeability, with 
-log Pe values of 3.97 ± 0.14 and 3.52 ± 0.20, respectively. Intermediate BBB 
permeability was seen for both GEN and DAI, with -log Pe values of 4.26 ± 0.16 and 
4.53 ± 0.13, respectively. SECO and ED exhibited low permeability through the BBB.  
Isoflavones and Lignans Show No Cytotoxicity in Murine Microglia 
Isoflavones were administered at 20 μM, while lignans were dosed at 10 μM. 
Parent polyphenols and PMMs were evaluated for cytotoxicity in murine microglia 
after a 24 h incubation period (Figure 4A,5A). There were no significant reductions in 
cellular viability at each of the test concentrations, thus indicating nontoxic levels.  
Isoflavones Reduce NOS Production 
Isoflavones were evaluated for their ability to reduce nitric oxide production after 
LPS induction, as determined by the Griess Reagent (Figure 4B). Cells treated with 
LPS produced 41.5 ± 5.6 μM NOS, significantly more than the control (0.4 ± 0.02 
μM). GEN significantly reduced nitric oxide at both 20 and 10 μM by 68% and 38%, 
respectively as compared to LPS alone. At 20 μM, DAI and EQ also significantly 
reduced nitric oxide compared to LPS by 24 and 22%, respectively.  
Isoflavones Reduce Pro-Inflammatory Cytokine Release 
 73 
 
TNF-a was increased significantly to 687.7 ± 8.0 pg/mL after LPS stimulation, 
compared to the unstimulated control, 115.4 ± 2.8 pg/mL (Figure 4C). All three 
isoflavones significantly reduced TNF-a production compared to the LPS-induced 
treatment. GEN reduced TNF-a, by 29.1% and 16.6% at concentrations of 20 and 10 
μM, respectively. DAI and EQ exhibited similar, albeit less potent, protective abilities 
at both the high (20 μM) and low (10 μM) concentrations (Figure 4C). IL-6 production 
was significantly increased by LPS (103.7 ± 3.6 pg/mL) compared to the control (0.6 ± 
0.05 pg/mL) (Figure 4D). All isoflavones were able to significantly reduce IL-6 
production compared to the LPS-induced treatment. GEN was the most effective, 
reducing IL-6 production by 80.4 and 34.0% at 20 and 10 μM, respectively (Figure 
4D).  
ANOVA followed by Tukey’s post hoc test was used to determine significant 
differences amongst test compounds and anti-inflammatory potential. The 20 μM 
dose of GEN resulted in significantly reduced concentrations of NOS, TNF-α, and IL-6 
compared to all other test compounds and concentrations (Tables S1–S3 in 
supplementary files), clearly showing GEN as the most potent anti-inflammatory 
metabolite of the isoflavones and PMMs tested. 
Lignans Limit NOS Production 
Nitric oxide concentrations for vehicle-treated microglia were approximately 11.97 
μM ± 0.07, whereas LPS stimulation increased this concentration to 51.01 μM ± 1.23. 
SECO, ED and EL decreased nitric oxide release by approximately 9.13 (46.35 μM ± 
0.22), 8.54 (46.65 μM ± 0.36) and 30.07% (35.67 μM ± 0.74), respectively (Figure 
5B). 
SECO, ED and EL Significantly Reduce IL-6 and TNF-α 
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As expected, IL-6 and TNF-α concentrations were elevated in LPS-treated 
microglia with concentrations of 665.7 pg/mL ± 5.8, and 518.4 pg/mL ± 8.8, 
respectively (Figure 5C, 5D). IL-6 concentration decreased by 1.05 % (672.8 pg/mL 
±13.9) in samples treated with SECO. ED and EL pre-treated conditions decreased 
the release of IL-6 by approximately 3.74% (690.6 pg/mL ± 5.30) and 26.41% (489.9 
pg/mL ± 11.31), respectively. With respect to TNF-α, SECO, ED and EL reduced 
cytokine release by 3.97% (497.8 pg/mL ± 12.42), 0.5% (515.8 pg/mL ± 7.12) and 
29.47% (365.6 pg/mL ± 4.91), respectively. Like GEN above, EL showed significantly 
greater reduction of inflammatory cytokines when compared to SECO and EL (Tables 
S4-S6). 
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Discussion 
The overall health of humans and communities depends on many factors 
including genetics, various environmental factors, and diet. Increased adherence to 
the Mediterranean diet was recently correlated with a reduced risk of 
neurodegenerative diseases, including prodromal Parkinson’s disease [5,42]. In this 
report, we sought to explore two common classes of polyphenols found in the 
Mediterranean diet, namely isoflavones and lignans, to investigate the bioavailability 
and bioactivity of these compounds and their metabolites.  
Previously published literature suggests that for polyphenols to be bioactive, they 
must first be transformed in the colon by the gut microbiota into molecularly unique 
metabolites [16]. Compounds which are permeable through the gut mucosa enter the 
bloodstream and circulate in the body. The in vivo permeability may change if these 
substances are compatible with active transporters, as well as differences based on 
the individual’s GI environment and diet [43]. A number of factors contribute to the 
absorption ability of a compound, namely, physicochemical (e.g., pKa, solubility, 
polarity), physiological (e.g., GI pH, GI blood flow), and dosage form (e.g., tablet, 
capsule) [44].  
To investigate the role of lignans, isoflavones, and PMMs in systemic circulation, 
we explored gut permeability through in silico (SwissADME) and in vitro (PAMPA) 
models. Gut PAMPA results largely coincided with those of in silico predictions and 
showed that the test compounds, with the exception of ED, passively permeate the 
gut. The presence of O-methyls on SECO and lactone moiety on EL may provide 
these molecules with additional lipophilicity needed to cross the membrane (Figure 
1), whereas ED contains free hydroxyl groups, which may reduce passive 
permeability. These data are supported by previously published results such as the 
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evaluation of GI absorption of alkaloids from Coptis [45]. PAMPA is a useful tool for 
predicting a compound’s permeability through the human gut, however, it only 
considers the rate of passive transport [36]. 
The BBB serves as a protective barrier of the brain, comprised of endothelial 
cells that create tight junctions, allowing for extremely selective passive permeability 
[40]. This typically results in higher penetrability by lipophilic compounds through the 
BBB [46]. Compounds that pass through the BBB may influence the brain state and 
physiology. We sought to identify if the aforementioned isoflavones, lignans, and 
PMMs can passively cross the BBB and could be relevant in modulating the 
pathogenic features of neurodegenerative diseases. 
Computational predictive software, SwissADME, identified EL, DAI and EQ as 
BBB-penetrable molecules. Interestingly, neither GEN nor SECO were considered 
permeable. Furthermore, our PAMPA in vitro study supported these results, reporting 
high permeability of EL and EQ. SECO and ED exhibited no apparent permeability. 
The parent compounds of isoflavones, GEN and DAI, were identified as intermediate 
permeable compounds. Similar investigative strategies have identified high 
permeability of compounds derived from natural sources through PAMPA–BBB [47]. 
While there are many other factors that contribute to BBB permeability, such as 
plasma concentration, plasma binding, and metabolic modifications by barrier 
enzymes, PAMPA is a good predictor of passive movement across the BBB [35,46]. 
The relationship between gut and BBB permeability is further complicated by 
presystemic metabolism. For instance, previous studies have shown that following gut 
metabolism, EL predominantly exists as a glucuronide conjugate, certainly affecting 
its BBB permeability and overall bioavailability [48].  
We identified that these PMMs, specifically EL and EQ, passively cross both the 
gut and BBB barriers. To further identify the potential bioactivities of these molecules, 
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we examined their protective ability against inflammation in microglia. Microglia are 
the resident macrophages of the brain that work to eliminate debris from the brain 
[48]. However, continuous activation of microglia can lead to the over-production of 
inflammatory cytokines, as identified in postmortem brains of Alzheimer’s and 
Parkinson’s disease patients [49]. One mechanism of microglia activation is the 
increase in LPS levels in peripheral blood, due to poor diet [50,51]. The continued 
elevated levels of these pro-inflammatory cytokines, specifically IL-6 and TNF-a, can 
stimulate the recruitment and activation of other microglia, further inducing the 
production of reactive oxygen species and nitric oxide species [52]. NOS at low doses 
is critical for maintaining healthy microglia and neuron function, but at high doses can 
induce necrosis or apoptosis [53]. Phenolic compounds have previously been linked 
to reduced microglia-induced neuroinflammation [54]. At 20 µM, all tested isoflavones 
were able to significantly reduce nitric oxide production, and TNF-α and IL-6 
concentrations compared to LPS alone. These results are consistent with previous 
reports of isoflavones [14]. However, GEN clearly showed the greatest anti-
inflammatory properties when compared to SECO and EQ. Furthermore, we 
subjected SECO and its microbial-derived metabolites to neuroprotective assays.  
Among the lignans tested, only the gut-derived metabolite EL was able to significantly 
reduce IL-6 and TNF-a production. Additionally, EL showed significantly greater 
reduction in nitric oxide concentrations than its parent metabolite and ED. Recent 
studies with certain polyphenol metabolites, namely, gallic acid derivatives, 
demonstrated that these metabolites pass across BBB endothelium and provide 
neuroprotective effects through modulation of the NF-κB pathway [55]. It is clear from 
these previous studies and the work presented here that the neuroprotective potential 
 78 
 
of BBB-permeable metabolites is an important area for further investigation to 
understand the relationship between dietary intake of polyphenols and brain health. 
In summary, the fate of microbial metabolites is largely governed by their ability 
to permeate through biological barriers. After investigating two classes of polyphenols 
often found in the Mediterranean diet, namely, isoflavones and lignans, our data 
suggest that their gut microbial metabolites, but not parent compounds, may enter the 
blood, cross the BBB and provide protection against neuroinflammation. The 
isoflavone parent compound, DAI, exhibits high gut permeability, but intermediate 
BBB permeability. DAI’s microbial metabolite, EQ, exhibits high permeability in both 
the gut and BBB, as well as significantly reducing nitric oxide and the production of 
pro-inflammatory cytokines in murine microglia. GEN shows permeability through 
both the gut and BBB and very strong anti-inflammatory effects. However, gut 
microbial metabolism would likely limit the circulating levels of GEN in the blood. The 
lignan SECO has extremely limited membrane permeability, but its gut microbial 
metabolite EL passively penetrates both the gut and BBB. Additionally, EL was most 
effective out of the lignans tested in inhibiting NOS and pro-inflammatory cytokines in 
vitro.  
These data, supported by previously published literature, suggest the further 
investigation of gut-microbial-derived metabolites, specifically EL and EQ, for the 
treatment of neurodegenerative diseases both in vitro and in vivo. Furthermore, using 
a system like PAMPA can aid in refining in vitro testing to ultimately inform the design 
of more efficacious animal studies. 
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Figure 1. Overview of the polyphenol isoflavones and lignan parent 
compounds and their respective polyphenol microbial metabolites produced 
by gut microflora. (Genistein = GEN, daidzein = DAI, equol = EQ, 
secoisolariciresinol = SECO, enterodiol = ED, enterolactone = EL). 
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Table 1. In silico SwissADME predictive permeability of parent polyphenols 
and their microbial metabolites in the gut and blood–brain barrier (BBB). 
Compound 
Molecular 
Weight 
(g/mol) 
Gut 
Absorption 
BBB 
Permeability 
SECO 362.42  High No 
ED 302.36  High No 
EL 298.33  High Yes 
GEN 270.24  High No 
DAI 254.24 High Yes 
EQ 242.27 High Yes 
Antipyrine 188.23 High Yes 
Corticosterone 346.46 High Yes 
Ketoprofen 254.28 High Yes 
Ranitidine 314.40 High No 
Theophylline 180.16 High No 
Verapamil  454.60 High Yes 
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Figure 2. Parallel artificial membrane permeability assay (PAMPA) gut 
passive permeability at three relevant pH levels: 5.0 (A), 6.2 (B), and 7.4 (C). 
Controls verapamil, antipyrine and ranitidine exhibit high, medium and low 
penetrability, respectively. Ketoprofen shows variable permeability with pH 
change. 
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Figure 3. Assessment of blood–brain barrier passive permeability of 
polyphenols determined by PAMPA. Positive (verapamil), intermediate 
(corticosterone) and low (theophylline) permeability controls. 
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Figure 4. Effects of isoflavones against LPS-induced oxidative stress in BV-
2 murine microglia. Isoflavones exhibited no cytotoxic effects in murine 
microglia (A). Isoflavones (20 µM and 10 µM) reduce nitric oxide production, 
as determined by the Griess Reagent (B). Isoflavones inhibited the 
production of the pro-inflammatory cytokines, TNF-a (C) and IL-6 (D), in 
murine microglia. All data expressed as mean ± standard error (n ≥ 3), 
significance was reported by analysis of variance (ANOVA) followed with 
Dunnett multiple comparison testing. Significance as compared with control 
p ≤ 0.0001 (####); as compared with LPS, p ≤ 0.03 (*), p ≤ 0.002 (**), p ≤ 
0.0002 (***) and p ≤ 0.0001 (****). 
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Figure 5. Effects of lignans in murine microglia cells. Lignans were 
evaluated for cytotoxicity in BV-2 (A). Effect of lignan treatment (10 µM) on 
nitric oxide production, as determined by the Griess Reagent (B). Lignans 
reduce the production of pro-inflammatory cytokines in murine microglia, 
TNF-a (C) and IL-6 (D). All data expressed as mean ± standard error (n ≥ 3), 
significance was reported by analysis of variance (ANOVA) followed with 
Dunnett multiple comparison testing. Significance as compared with control 
p ≤ 0.0001 (####); as compared with LPS, p ≤ 0.002 (**), p ≤ 0.0002 (***) 
and p ≤ 0.0001 (****). 
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Abstract 
 
Parkinson’s disease is a complex neurodegenerative disease that attacks 
dopaminergic neurons of the substantia nigra, resulting in a variety of locomotor 
deficits. Disease severity, progression, and drug response appear to be influenced by 
gender, suggesting a protective role of estrogen. Phytoestrogens, genistein, daidzein, 
and gut-derived microbial metabolite equol, exhibit antioxidant activity, alleviate 
oxidative stress, and most recently show neuroprotective ability. Herein, we 
investigate these three phytoestrogens’ for their protective abilities against toxin-
induced models of Parkinson’s disease. In a co-culture model, isoflavones 
significantly improved cellular viability as compared to LPS-induced murine microglia 
cell supernatant. Equol was most successful in protecting against neuronal cell death 
induced by 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+), 
improving cell viability by 31% and 18% at 20 μM, respectively. Parent compounds, 
genistein, and daidzein, failed to consistently improve cellular viability. Therefore, 
equol was assessed in Caenorhabditis elegans and Drosophila melanogaster. In C. 
elegans, equol significantly improved lifespan as compared to toxic agent MPP+. In D. 
melanogaster, equol treatment for 7 days exhibited minor improvements in climbing 
ability as compared to 6-OHDA alone. Moreover, our data suggest a potentially 
protective role of equol, but not parent compounds, against toxic models of 
Parkinson’s disease.  
Keywords: Parkinson’s disease, phytoestrogens, isoflavones 
 
Abbreviations: PD: Parkinson’s disease, ERb: Estrogen receptor b, EST: 17b-
Estradiol, GEN: Genistein, DAI: Daidzein, EQ: S-Equol, LPS: Lipopolysaccharide, 6-
OHDA: 6-Hydroxydopamine, MPP+: 1-Methyl-4-phenylpyridinium 
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Introduction 
 
 Parkinson’s disease (PD) is a multifaceted neurodegenerative disease that 
can present as a wide variety of symptoms, but a clinical diagnosis is determined by 
the presence of motor difficulties such as tremors, bradykinesias, rigidity and postural 
instability, and exclusion of any other diseases1. PD is anticipated to affect 930,000 
by 20202. Pathological characteristics of PD are the loss of dopamine specifically in 
the substantia nigra, as well as the accumulation of a-synuclein3. Pharmaceutical 
interventions primarily focus on replenishing the lost dopamine, typical treatment 
includes levodopa coupled with a dopamine decarboxylase inhibitor4. Recent focus 
has shifted to stop the progression of the disease by exploring alternative targets 
such as genetic mutations or neuroinflammation5,6. Interestingly, PD progression, 
incident rates, and pharmaceutical response seem to be influenced by gender7. For 
instance, male prevalence rates are 1.5 times higher than in females8. Additionally, 
risk substantially increases in females after menopause, suggesting a potential 
protective role of estrogen against PD9.  
 The protective role of estrogen in PD has been explored in multiple recent 
studies. In mice, estrogen treatment modified the activation of astroglia and microglia, 
and nigrostriatal disruption against toxin-induced PD10. Similarly, a recent clinical 
study compared striatal dopamine transporter (DAT) availability in females, reporting 
lower DAT in the brain, suggesting estrogen may have a beneficial effect on 
dopaminergic neurons11. Taken together, these studies support a protective role for 
estrogen against PD. A systematic meta-analysis found no positive relationship 
between hormone replacement therapy and a decreased risk in PD12. This 
discrepancy may be due to the massive role estrogen plays throughout the body.  
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 Therefore, we hypothesize that naturally occurring estrogens may have similar 
neuroprotective abilities without performing all estrogenic activities. Phytoestrogens 
classified as isoflavones exhibit excessive antioxidant activity, alleviate oxidative 
stress, and selectively bind to ER-b13–17. The two most common isoflavones, genistein 
(GEN) and daidzein (DAI) are found primarily in soy and have been extensively 
studied. Previous reports show GEN inhibits mitochondria-dependent apoptosis, and 
alleviates b-amyloid neurotoxicity, providing neuroprotection18–20. Similarly, DAI 
demonstrates pro-apoptotic and neurotoxic effects against glutamate treatment21. The 
bioavailability of these compounds after consumption has been disputed, evidence 
suggests that gut microbial-derived metabolites are much more abundant22. Gut 
microbial metabolite, equol (EQ), has been shown to protect against cardiovascular 
disease, bone health, and specific cancers23,24. In our recent publication, we showed 
that of these isoflavones, EQ is most likely to cross the blood-brain barrier and 
protects against inflammation in murine microglia models25.  
As phytoestrogens and known agonists of estrogen receptor beta (ER-b), we 
hypothesized that these isoflavones, EQ, in particular, will provide protection in 
Parkinson’s disease models. Herein, we evaluate positive control 17b-estradiol, 
genistein, daidzein and equol in toxin-induced models of Parkinson’s disease in cells, 
Caenorhabditis elegans and Drosophila melanogaster. 
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Materials and Methods  
 
Chemicals  
 Dimethylsulfoxide (DMSO), lipopolysaccharide (LPS), 6-hydroxydopamine (6-
OHDA) and 1-methyl-4-phenylpyridinium (MPP+) were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). DMEM/F-12, phenol red-free DMEM medium, 
and trypsin-versene were purchased from Life Technologies (Grand Island, NY, 
USA).  
Compounds 
17b-Estradiol (EST), daidzein (DAI), and genistein (GEN) were purchased 
from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). S-Equol (EQ) was purchased 
from Chembest (Shanghai, China).  
Cell Culture Maintenance 
Murine microglia (BV-2) were generously gifted by Dr. Grace Y. Sun 
(University of Missouri at Columbia, MO, USA). Human neuroblastoma (SH-SY5Y) 
were obtained from American Type Culture Collection (ATCC, VA, USA). Cells were 
maintained in DMEM/F-12 high glucose (4.5 g/L), supplemented with 10% inactivated 
FBS and 1% P/S (100 U/mL penicillin, 100 mg/mL streptomycin) (Life Technologies, 
Gaithersburg, MD, USA) at 37°C in 5% CO2. EST and isoflavones were prepared to 
10 mM in DMSO, and further diluted in serum-free DMEM/F-12 media. Control wells 
contained 0.1% DMSO. 
Cytotoxicity Screen  
Cytotoxicity of compounds at 20 µM in SH-SY5Y were assessed with Cell 
Titer Glo 2.0 (CTG) (Promega, Madison, WI, USA) after 24 h treatment, cell viability 
was determined as percentage of control26. 
Non-Contact Co-Culture 
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The non-contact co-culture experiment was performed using treated media 
from BV-2 cells on human neuroblastoma, as previously described27. BV-2 were 
pretreated with isoflavones for 1 h, then induced with lipopolysaccharide (1mg/mL) for 
23 h. Media was removed from BV-2 and placed on SH-SY5Y, seeded in white-
walled 96-well plates at 100,000 cells/mL. SH-SY5Y were then incubated for 24 h, 
cell viability was then assessed using CTG. 
Cellular Viability against Toxic Agents 
Human neuroblastoma were seeded in white-walled 96-well plates at 100,000 
cells/mL for 24 h. Cells were incubated with corresponding treatments for 2 h in 
serum-free media, then induced with toxic agents for 24 h: 6-OHDA (100 μM) or 
MPP+ (2 mM). Cellular viability was determined by CTG, illustrated as percentage of 
control.  
Caenorhabditis elegans 
C. elegans were maintained and assayed for lifespan against MPP+ as previously 
described28. Briefly, wild type (N2) were maintained on normal nematode growth 
media at 20°C. Nematodes were age synchronized, and at L1 40 μL worms were 
plated in a 96-well microplate (approximately 20 worms/well). Worms were plated with 
Escherichia coli OP50 (5 mg/mL), MPP+ (750 μM), and Equol (17.5°C or 30 μM). 
Control groups received S-complete media. Post treatment, live worms were counted 
every 12 h until no live worms remained. 
Drosophila Melanogaster Maintenance and Treatment 
Canton S (w[*]) flies were a kind gift from Dr. Belinda Barbagallo (Salve 
Regina University, Newport, RI). Flies were maintained and age synchronized on 
Nutri-Fly BF (Genesee Scientific, San Diego, CA). On day 1 post eclosion, flies were 
separated by gender to approximately 20 flies per vial.  Treatments were added to the 
media on day 3 post eclosion, control received 5% sucrose and equol received 100 
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μM diluted in 5% sucrose. Treatment vials were exchanged every other day for 7 
days.  
Climbing Assay  
 After 7 days of treatment, flies were assayed for climbing ability28,29. Briefly, 
flies were placed in empty vials marked at 5 cm and allowed to acclimate for 30 
minutes. Flies were gently tapped to the bottom of the vial and a picture was taken 
after 10 seconds using a Nikon D2200 camera (Nikon, Tokyo, JP). Percent climbing 
was calculated by ((# flies above line / total # flies)*100).  
Statistical Analysis  
All data are reported as mean ±standard errors of at least three independent 
biological samples. Analysis of all cellular and Drosophila data were conducted by 
ANOVA followed by Dunnett’s test for multiple comparisons of group means. 
Significance of the toxic agent compared to the control group is presented as p≤0.01 
(##) and p≤0.0001 (####). Significance for tests compared to toxic treatment was 
defined as: p≤0.05 (*), p≤0.01 (**), p≤0.001 (***) and p≤0.0001 (****). Lifespan 
analysis for C. elegans identified using the Kaplan–Meier, tested for statistical 
significance using the log-rank test (Mantel-Cox). GraphPad Prism software 8.0 
(GraphPad Software, Inc., San Diego, CA) was used to create all graphs and for all 
statistical analysis calculations. 
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Results  
 
Cytotoxicity Screen 
Compounds were tested for cytotoxicity at 20 μM in neuroblastoma (Figure 1). 
No significant difference was seen between control and isoflavone treatment, 
indicating safe concentrations. 
Effects of Isoflavones in Non-Contact Co-Culture 
Treatment with LPS media reduced SH-SY5Y viability to 56.9 ± 1.2%, as 
compared to control, 100 ± 2.5% (Figure 2). Isoflavones at all concentrations 
exhibited significantly increased cellular viability as compared to LPS treatment alone. 
GEN significantly increased cellular viability by 11 and 6%, at 20 μM and 10 μM, 
respectively. Treatment with DAI (20 and 10 μM) increased cellular viability by 11 and 
16%. EQ significantly increased cellular viability by 17 and 14% at 20 and 10 μM, 
respectively. 
Human Neuroblastoma PD Model  
Human neuroblastoma (SH-SY5Y) were analyzed against PD toxic insults 6-
OHDA and MPP+ (Fig. 3). 6-OHDA significantly decreased cellular viability to 35.3% ± 
6.8, as compared to control (100 ± 6.5). DAI (20 μM) improved viability by 26%, 
compared to 6-OHDA. EQ at both concentrations increased cellular viability by 31 
and 27%, compared to toxic treatment.  
In the MPP+ model, control exhibited 100 ± 3.0% viability, whereas MPP+ 
treatment significantly reduced cellular viability to 57.8 ± 2.3%. DAI significantly 
increased cellular viability by 20 and 15% at 20 μM and 10 μM, respectively. 20 μM 
and 10 μM of EQ significantly improved cellular viability by 18% and 19%, as 
compared to MPP+. 
C. elegans Lifespan 
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 We further evaluate EQ against toxic agent, MPP+, in the C. elegans model. 
MPP+ treatment alone significantly reduced lifespan to 72 h (Fig. 4A). EQ at 17.5 and 
35 μM significantly improved the median lifespan to 108 h (Fig. 4B &C).  
Drosophila melanogaster Negative Geotaxis  
 D. melanogaster were evaluated for EQ (100 μM) protection against 6-OHDA 
toxicity in the negative geotaxis assay (Fig. 5). 6-OHDA treatment for one week failed 
to significantly reduce the climbing ability of male flies. EQ treatment exhibited 
increased climbing ability as compared to 6-OHDA, however not significantly.  
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Discussion 
 
There has been an increased interest in flavonoids for the prevention of 
neurodegenerative diseases, as they exhibit the ability to cross the BBB and have a 
wide range of bioactive properties including antioxidant, anti-inflammatory, 
antiapoptotic and lipid-lowering properties30,31. PD is a neurodegenerative disease 
characterized by the loss of dopaminergic neurons in the substantia nigra, leading to 
tremors, bradykinesias, and further dementias. Dopaminergic neuronal death in PD 
has also been heavily linked to increases in neuroinflammation32. Endogenous 
estrogen exhibits the ability to reduce neuroinflammation and protects against 
neurodegeneration in PD33. Herein, we explored the effects of naturally occurring 
phytoestrogens, namely, isoflavones, in the protection against toxin-induced PD 
models in neuroblastoma and drosophila.  
Oxidative stress and inflammation induced by activated microglia have 
become key pathological features of PD, resulting in increased levels of cytokines 
and dopaminergic neuronal loss localized to the substantia nigra34,35. Multiple recent 
publications have identified a protective role of gut-derived microbial metabolite, 
equol, in astrocytes and microglia induced with LPS36,37. Further, we explored the 
relationship between activated microglia and neuronal death in vitro27. We show that 
EQ treatment in murine microglia followed by LPS-induced inflammation produces 
lower neuronal death in our co-culture experiment. This indicates that EQ may reduce 
oxidative and inflammatory stress in microglia, protecting neurons against toxic 
agents.  
Toxin-induced models of PD have proven to be useful in discoveries regarding 
the treatment and progression of the disease. Human neuroblastoma cell line SH-
SY5Y is heavily used in PD research as it has dopaminergic properties allowing for 
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PD-like phenotypes when induced with toxic agents such as 6-OHDA, or MPP+38. 6-
OHDA leads to the death of dopaminergic neurons, proposed to involve the 
generation of free radicals39. MPP+ mimics PD symptoms by altering mitochondrial 
function, leading to increased oxidative stress and abnormal protein aggregation39,40. 
EQ exhibited significant protection against both 6-OHDA and MPP+ induced toxicity in 
the neuroblastoma model. Although EQ has not previously been published in PD 
models of SH-SY5Y, it is in agreement with previous reports of a combination of 
GEN, DAI and EQ neuroprotective abilities41. Further in-vivo investigation supports 
this protective role of EQ against MPP+, but not 6-OHDA. Future investigations of EQ 
should explore both toxic and transgenic models of PD to determine mechanisms of 
protection.  
Herein, we report that gut microbial metabolite, Equol, exhibits neuroprotective 
activities in Parkinson’s disease models in vitro and in vivo. Highlighted by the 
reduction in toxin-related cell and C. elegans death. Our results warrant further 
investigation of Equol as a future intervention for PD.  
 
 
 
 
 
  
 
104 
Acknowledgements 
 
S.J. was supported by a fellowship from the George and Anne Ryan Institute for 
Neuroscience. Spectroscopic data were obtained from instruments located in the 
Rhode Island-IDeA Network for Excellence in Biomedical Research core facility 
supported by Grant # P20GM103430 from the National Institute of General Medical 
Sciences of the National Institutes of Health. 
 
Conflict of Interest 
 
The authors have declared no conflict of interest.  
 
 
  
 
105 
 
 
 
Figure 1. Cytotoxicity evaluation of isoflavones at 20 μM after 24h on human 
neuroblastoma (SHSY5Y). Data are expressed as mean ±standard error, presented 
as percentage compared to control (n³3).  
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Figure 2. Effects of isoflavone treated, LPS-induced murine microglia cell 
supernatant on human neuroblastoma cellular viability. Data are expressed as mean 
±standard error (n³3), reported as percentage compared to control. Statistical 
significance was evaluated using ANOVA followed with Dunnett’s multiple 
comparison test, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 as compared 
to control cells. Toxin insult was compared to control, ##p < 0.01. 
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Figure 3. Isoflavones protect against toxic inducers of PD in human neuroblastoma. 
Cells were treated, then exposed to 25 μM 6-OHDA (A) and 2 mM MPP+(B) for 24h, 
where cellular viability was assessed. Data are expressed as mean ±standard error, 
exhibited as percentage compared to control (n³6). Statistical significance was 
evaluated using ANOVA followed with Dunnett’s multiple comparison test, *p < 0.05, 
** p < 0.01, ***p < 0.001, and ****p < 0.0001. Toxin insult was compared to control, 
####p < 0.0001. 
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Figure 4. Effects of Equol (17.5 and 35 μM) on lifespan of C. elegans exposed to 
MPP+ (750 μM). Toxin reduces lifespan in control group (A). EQ at 17.5 (B) and 35 
μM (C) exhibit protective effects versus MPP+. Survival curves were statistically 
analyzed by log rank test (Mantel Cox), as compared to MPP+ treatment (n >100).  
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Figure 5. Effects of Equol on climbing ability of Drosophila melanogaster. Influence of 
equol (100 μM) treatment on wildtype flies alone and induced with 6-OHDA (1 mM) 
on climbing ability after 7 days of treatment.  
 
 
 
 
 
 
 
 
 
  
 
110 
References 
 
1. Jankovic, J. Parkinson ’ s disease : clinical features and diagnosis Parkinson ’ s 
disease : clinical features and diagnosis. J. Neurol. Neurosurg. Physiatry 368–
376 (2008). doi:10.1136/jnnp.2007.131045 
2. Marras, C. et al. Prevalence of Parkinson’s disease across North America. npj 
Park. Dis. 4, 21 (2018). 
3. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015). 
4. Stocchi, F. Therapy for Parkinson’s Disease: What is in the Pipeline? 
Neurotherapeutics 11, 24–33 (2014). 
5. Rane, P. et al. Novel targets for Parkinson’s Disease: Addressing different 
therapeutic paradigms and conundrums. ACS Chem. Neurosci. (2018). 
doi:10.1021/acschemneuro.8b00180 
6. Lee, Y., Lee, S., Chang, S. C. & Lee, J. Significant roles of neuroinflammation 
in Parkinson’s disease: therapeutic targets for PD prevention. Arch. Pharm. 
Res. 42, 416–425 (2019). 
7. Cerri, S., Mus, L. & Blandini, F. Parkinson’s Disease in Women and Men: 
What’s the Difference? J. Parkinsons. Dis. 9, 501–515 (2019). 
8. Moisan, F. et al. Parkinson disease male-to-female ratios increase with age: 
French nationwide study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 
0, 1–6 (2015). 
9. Labandeira-Garcia, J. L., Rodriguez-Perez, A. I., Valenzuela, R., Costa-
Besada, M. A. & Guerra, M. J. Menopause and Parkinson’s disease. 
Interaction between estrogens and brain renin-angiotensin system in 
dopaminergic degeneration. Front. Neuroendocrinol. 43, 44–59 (2016). 
10. Siani, F. et al. Influence of estrogen modulation on glia activation in a murine 
  
 
111 
model of parkinson’s disease. Front. Neurosci. 11, 1–11 (2017). 
11. Lee, Y. H. et al. Beneficial effect of estrogen on nigrostriatal dopaminergic 
neurons in drug-naïve postmenopausal Parkinson’s disease. Sci. Rep. 9, 1–9 
(2019). 
12. Wang, P., Li, J., Qiu, S., Wen, H. & Du, J. Hormone replacement therapy and 
parkinson’s disease risk in women: A meta-analysis of 14 observational 
studies. Neuropsychiatr. Dis. Treat. 11, 59–66 (2014). 
13. Amer, D. A. M. et al. Activation of transgenic estrogen receptor-beta by 
selected phytoestrogens in a stably transduced rat serotonergic cell line. J. 
Steroid Biochem. Mol. Biol. 120, 208–217 (2010). 
14. Muthyala, R. S. et al. Equol, a natural estrogenic metabolite from soy 
isoflavones: Convenient preparation and resolution of R- and S-equols and 
their differing binding and biological activity through estrogen receptors alpha 
and beta. Bioorganic Med. Chem. 12, 1559–1567 (2004). 
15. Rufer, C. E. & Kulling, S. E. Antioxidant activity of isoflavones and their major 
metabolites using different in vitro assays. J Agric Food Chem 54, 2926–2931 
(2006). 
16. Ma, Y., Sullivan, J. C. & Schreihofer, D. A. Dietary genistein and equol (4’, 7 
isoflavandiol) reduce oxidative stress and protect rats against focal cerebral 
ischemia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R871-7 (2010). 
17. Kunisue, T., Tanabe, S., Isobe, T., Aldous, K. M. & Kannan, K. Profiles of 
phytoestrogens in human urine from several Asian countries. J. Agric. Food 
Chem. 58, 9838–9846 (2010). 
18. Bang, O. Y. et al. Neuroprotective effect of genistein against beta amyloid-
induced neurotoxicity. Neurobiol. Dis. 16, 21–28 (2004). 
19. Ma, W. et al. Genistein alleviates β-amyloid-induced inflammatory damage 
  
 
112 
through regulating Toll-like receptor 4/nuclear factor κB. J. Med. Food 18, 273–
9 (2015). 
20. Qian, Y. et al. Neuroprotection by the soy isoflavone, genistein, via inhibition of 
mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-
??B activation in a cerebral ischemia mouse model. Neurochem. Int. 60, 759–
767 (2012). 
21. Kajta, M. et al. The Key Involvement Of Estrogen Receptor B And G-Protein-
Coupled Receptor 30 In The Neuroprotective Action Of Daidzein. 
Neuroscience 238, 345–360 (2013). 
22. Yuan, T. et al. Pomegranate’s Neuroprotective Effects against Alzheimer’s 
Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived 
Metabolites. ACS Chem. Neurosci. acschemneuro.5b00260 (2015). 
doi:10.1021/acschemneuro.5b00260 
23. Setchell, K. D. R. et al. S-equol, a potent ligand for estrogen receptor b, is the 
exclusive enantiomeric form of the soy isoflavone metabolite produced by 
human intestinal bacterial flora. in American Journal of Clinical Nutrition 81, 
1072–1079 (2005). 
24. Yuan, J. P., Wang, J. H. & Liu, X. Metabolism of dietary soy isoflavones to 
equol by human intestinal microflora - Implications for health. Mol. Nutr. Food 
Res. 51, 765–781 (2007). 
25. Johnson, S. L. et al. Polyphenol Microbial Metabolites Exhibit Gut and Blood–
Brain Barrier Permeability and Protect Murine Microglia against LPS-Induced 
Inflammation. Metabolites 9, 78 (2019). 
26. Ma, H. et al. Evaluation of polyphenol anthocyanin-enriched extracts of 
blackberry, black raspberry, blueberry, cranberry, red raspberry, and 
strawberry for free radical scavenging, reactive carbonyl species trapping, anti-
  
 
113 
glycation, anti-β-amyloid aggregation, and mic. Int. J. Mol. Sci. 19, (2018). 
27. Ma, H. et al. Effects of a Standardized Phenolic-Enriched Maple Syrup Extract 
on β-Amyloid Aggregation, Neuroinflammation in Microglial and Neuronal 
Cells, and β-Amyloid Induced Neurotoxicity in Caenorhabditis elegans. 
Neurochem. Res. (2016). doi:10.1007/s11064-016-1998-6 
28. Johnson, S. L. et al. Levodopa-reduced mucuna pruriens seed extract shows 
neuroprotective effects against parkinson’s disease in murine microglia and 
human neuroblastoma cells, Caenorhabditis elegans, and Drosophila 
melanogaster. Nutrients 10, 1–14 (2018). 
29. Phom, L., Achumi, B., Alone, D. P., Muralidhara & Yenisetti, S. C. Curcumin’s 
Neuroprotective Efficacy in Drosophila Model of Idiopathic Parkinson’s Disease 
Is Phase Specific: Implication of its Therapeutic Effectiveness. Rejuvenation 
Res. 17, 481–489 (2014). 
30. Braga, R. et al. Review Article Flavonoids as Therapeutic Agents in Alzheimer ’ 
s and Parkinson ’ s Diseases : A Systematic Review of Preclinical Evidences. 
Oxid. Med. Cell. Longev. (2018). doi:10.1155/2018/7043213 
31. Jung, U. J. & Kim, S. R. Beneficial Effects of Flavonoids Against Parkinson’s 
Disease. J. Med. Food 21, jmf.2017.4078 (2018). 
32. Hwang, O. Role of oxidative stress in Parkinson’s disease. Exp. Neurobiol. 22, 
11–7 (2013). 
33. Villa, A., Vegeto, E., Poletti, A. & Maggi, A. Estrogens, Neuroinflammation, and 
Neurodegeneration. 37, 372–402 (2016). 
34. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson’s disease: a target 
for neuroprotection? Lancet Neurol. 8, 382–397 (2009). 
35. Kim, Y. S. & Joh, T. H. Microglia, major player in the brain inflammation: their 
roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med. 38, 333–347 
  
 
114 
(2006). 
36. Moriyama, M. et al. S-equol, a major isoflavone from soybean, inhibits nitric 
oxide production in lipopolysaccharide-stimulated rat astrocytes partially via the 
GPR30-mediated pathway. Int. J. Inflam. 2018, (2018). 
37. Subedi, L. et al. Equol, a Dietary Daidzein Gut Metabolite Attenuates Microglial 
Activation and Potentiates Neuroprotection In Vitro. Nutrients 9, 207 (2017). 
38. Xicoy, H., Wieringa, B. & Martens, G. J. M. The SH-SY5Y cell line in 
Parkinson’s disease research: a systematic review. Mol. Neurodegener. 12, 10 
(2017). 
39. Shimohama, S., Sawada, H., Kitamura, Y. & Taniguchi, T. Disease model: 
Parkinson’s disease. Trends Mol. Med. 9, 360–365 (2003). 
40. Dauer, W. & Przedborski, S. Parkinson’s Disease: Mechanisms and Models. 
Neuron 39, 889–909 (2003). 
41. Zhao, L., Mao, Z. & Brinton, R. D. A select combination of clinically relevant 
phytoestrogens enhances estrogen receptor ??-binding Selectivity and 
neuroprotective activities in vitro and in vivo. Endocrinology 150, 770–783 
(2009). 
 
  
 
115 
CHAPTER 3 
MANUSCRIPT 5 
 
Direct thrombin inhibitor, Dabigatran, protects against neuroinflammation in 
LRRK2 transgenic Drosophila melanogaster model of Parkinson’s disease 
 
Shelby L. Johnsona,b, Jaclyn Iannuccia,b, Navindra P. Seerama,b, Paula Grammasa,b  
 
a The George and Anne Ryan Institute for Neuroscience, University of Rhode 
Island, Kingston, RI, 02881 
b Department of Biomedical and Pharmaceutical Sciences, College of 
Pharmacy, University of Rhode Island, Kingston, RI, 02881 
 
 
  
 
116 
 
Abstract 
 
Parkinson’s disease (PD) is a complex neurodegenerative disease 
characterized by the presence of tremors, loss of dopaminergic neurons and 
accumulation of a-synuclein. While there is no single direct cause of PD, genetic 
mutations, exposure to pesticides, diet and traumatic brain injury have been identified 
as risk factors. Increasing evidence supports that activated microglia, and the 
resulting neuroinflammation plays a critical role in disease progression. Our lab has 
previously identified the neurotoxic role of thrombin, linked to neuroinflammation. For 
the first time, we explore direct thrombin inhibitor, dabigatran, in a transgenic 
Parkinson’s disease Drosophila melanogaster model. After 7 days of dabigatran 
treatment, male flies exhibited significant improvement in climbing ability, as 
compared to the vehicle. To elucidate the mechanism of locomotor protection, we 
investigate the production of nitric oxide (NOS) and reactive oxygen species (ROS). 
Dabigatran significantly reduced both NOS and ROS in male transgenic fly head 
homogenates. Western blot analysis confirmed that iNOS correlates with NOS 
production in male flies. SOD1 and NOX4 expression were reduced with dabigatran 
treatment, potentially contributing to ROS reduction. Our results indicate that 
dabigatran treatment improves motor function by reducing oxidative stress. We 
propose that inhibiting thrombin may provide a new therapeutic opportunity for 
potentially reducing PD associated pathologies. These initial findings should be 
investigated in alternative transgenic models of PD and evaluated for effects on 
behavior as well as biochemical markers of pathology to further elucidate 
mechanisms of action.  
Keywords: Parkinson’s disease, Dabigatran, Neuroinflammation   
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Introduction 
 
 Neurodegenerative diseases currently cost the United States billions of dollars 
annually1,2. The two most common neurodegenerative diseases are Alzheimer’s (AD) 
and Parkinson’s disease (PD)3,4. Currently, there are no interventions that can stop 
disease progression. Although the symptoms and disease progression of AD and PD 
are vastly different, both diseases are associated with protein aggregation, genetic 
predisposition, mitochondrial dysfunction, and neuroinflammation5.  
Neuroinflammation has been recognized as a major factor in the pathogenesis 
AD and PD1,2,6–10. The neuroinflammatory response in AD and PD is similar, 
characterized by phenotypic alterations in several cell types, including astrocytes, 
microglia, and endothelial cells5. Under normal conditions, microglia work to detect 
pathogens or tissue damage and elicit a response to clear cellular debris and 
degenerating cells10. However, when microglia are continuously activated by external 
stimuli, such as aggregated protein or foreign pathogens, this response can 
exacerbate disease conditions and lead to further neuronal damage11. This toxic 
microglial inflammatory response includes the release of a variety of inflammatory 
mediators, such as chemokines, cytokines, cyclooxygenase-2 (COX-2), and reactive 
mediators, namely, reactive oxygen species (ROS) and nitric oxide species 
(NOS)10,12,13. The chronic production of these inflammatory mediators increases 
oxidative stress and contributes to neuronal death. Although quite complex, 
neuroinflammation plays a major role in neurodegenerative diseases and has been 
identified as a worthy target for pharmaceutical interventions in neurodegenerative 
diseases.  
Cerebrovascular activation has been identified as a toxic contributor to both 
neuroinflammation and neurodegenerative diseases. Vascular activation is the result 
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of endothelial cell damage and leads to the upregulation of a number of noxious 
factors. One such factor is the protease thrombin, which is produced by injured 
endothelial cells both in vivo and in vitro, initiating a neurotoxic cascade14–16. Elevated 
levels of thrombin can be lethal to neurons through the interaction with protease 
activated receptor 1 (PAR-1), leading to the release of ROS and increases in an array 
of inflammatory proteins17,18. Cerebrovascular activation is likely present in both AD 
and PD, and increased levels of both thrombin and PAR-1 have been identified in 
both diseases19.  
Our lab has been interested in evaluating the direct thrombin inhibitor, 
Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim), for the treatment of vascular 
dysfunction in AD14,18. Multiple studies have shown dabigatran treatment mitigates the 
neurotoxic effects of thrombin in transgenic AD models14,20,21. A single publication 
previously explored dabigatran etexilate in a rotenone-induced rat model of PD, 
exhibiting neuroprotective effects through nuclear receptor-related 1 protein22. 
Dabigatran treatment is yet to be explored in transgenic models of PD.  
Therefore, we utilize a Drosophila melanogaster model of PD expressing 
mutant leucine-rich repeat kinase 2 (LRRK2). Drosophila melanogaster have been 
heavily used in neuroscience research as their neuronal structures and circuits and 
neurotransmitters, such as dopamine, are similar to those found in the human brain23–
25. When dopamine is dysfunctional in Drosophila, locomotion is impaired, similar to 
symptoms seen in human PD26. Leucine-rich repeat kinase 2 (LRRK2) has been 
identified in both idiopathic and inherited PD, accounting for as high as 40% of 
familial cases27. Postmortem analysis revealed LRRK2 is heavily expressed in the 
Lewy bodies of the brain stem and cortex, as well as in the brain vasculature, axons, 
and neuronal cell bodies28,29. LRRK2 mutant Drosophila exhibit reduced lifespan, 
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compromised motility, and mitochondria morphological changes as compared to 
wildtype30.  
Herein, we hypothesize that dabigatran treatment in LRRK2 transgenic 
Drosophila melanogaster will protect against motor function deficits by reducing 
oxidative stress.  
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Materials and Methods 
 
Drosophila Melanogaster Maintenance and Treatment 
LRRK2 mutant Drosophila melanogaster (#34750, w[*]; Lrrk[ex1]/TM6B, Tb[1]) 
were purchased from Bloomington Stock Center (Indiana University Bloomington, 
Bloomington, IN). Canton S (w[*]) flies were a kind gift from Dr. Belinda Barbagallo 
(Salve Regina University, Newport, RI). Flies were maintained and age synchronized 
on Nutri-Fly BF (Genesee Scientific, San Diego, CA). Flies were separated by gender 
to approximately 20 flies per vial. On day 3 post eclosion, corresponding treatments 
were added to the media, control received 5% sucrose and dabigatran received 25 
μM diluted in 5% sucrose. Treatment vials were exchanged every other day for 7 
days.  
 
Toxicity Analysis  
Toxicity of dabigatran at 25 μM was identified by recording deaths per vial 
every other day. At least 100 individual flies per treatment were monitored and 
evaluated over the course of one week.  
 
Negative Geotaxis Assay  
 After 7 days of treatment, flies were assayed for climbing ability31,32. Briefly, 
flies were placed in empty vials marked at 5 cm and allowed to acclimate for 30 
minutes. Flies were gently tapped to the bottom of the vial and a picture was taken 
after 10 seconds using a Nikon D2200 camera (Nikon, Tokyo, JP). Percent climbing 
was calculated by ((# flies above line / total # flies)*100) and standardized as a 
percentage to control (gender-specific).  
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Drosophila Head Homogenization  
 Drosophila were flash-frozen on dry ice and heads were collected through 
brass sieves, as previously reported33. Heads were counted and 10 μL/head of 
phosphate buffered saline was added for NOS and ROS. For western blots, fly heads 
were homogenized in phosphate buffered saline with 1X protease inhibitors. Samples 
were frozen immediately on dry ice and stored at -80°C. To homogenize the heads 
for assays, they were sonicated in a water bath for 5 min, centrifuged (10,000 RCF, 5 
min, 4°C), then placed at -80°C until frozen. This process was repeated 3 times and 
the supernatant was collected.  
 
Nitric Oxide Quantification  
Nitric oxide species was quantified in fly head homogenates using the Griess 
Reagent System (Promega, Madison, WI, USA)34. 
 
Reactive Oxygen Species Relative Quantification 
For reactive oxygen species relative quantification, homogenates were 
incubated with 20 μM 2’,7’-Dichlorofluorescin Diacetate (DCFDA) at 37℃ for 1h in a 
black-walled, clear-bottom 96-well plate. Fluorescence was then read on Spectramax 
(M2) plate reader at  485 nm excitation and 535 nm emission35.  
 
Western Blotting  
Fly head homogenate samples were prepared for western blot by adding 40% 
4x Sample buffer (4x Laemmli Sample Buffer (BioRad, Hercules, CA, USA) with 10% 
2-mercaptoethonal), heated at 100°C for 10 minutes. 15 µg of total protein was 
loaded on a 4-20% Gel (Invitrogen, Carlsbad, CA) and ran for 1h and 5min at 105 V 
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in 1x SDS-running buffer. Proteins were transferred to nitrocellulose membranes 
using the iBlot2 Gel Transfer Device (ThermoFisher Scientific, Waltham, MA), and 
membranes were blocked for 1h using 5% bovine serum albumin (BSA) in 0.05% 
TBS-T. Primary antibodies were incubated at room temperature for 3 hours, and then 
over 3 nights at 4°C. Primary antibodies used for this study include iNOS (Abcam, 
MA, 1:500), NOX4 (Sigma-Aldrich, MO, 1:500), SOD1 (Abcam, MA, 1:1,000), 
Tyrosine Hydroxylase (TH) (Novus Biologicals, Co, 1:500), and B-actin (Santa Cruz, 
CA, 1:10,000). Membranes were washed three times for 10 minutes with 0.05% TBS-
T and incubated with infrared secondary antibodies at room temperature for 1 h. 
Membranes were washed and imaged on a LiCor Odyssey (LI-COR Biosciences, 
Lincoln, NE). Western blots were quantified in ImageJ. Values for each protein were 
normalized to β-actin loading control on the same blot. Data are represented as fold 
change, as compared to gender-specific wild type control.  
 
Statistical Analysis  
All statistical analysis was performed in GraphPad Prism 8 (GraphPad 
Software, Inc., San Diego, CA, USA). For toxicity analysis, log-rank (Mantel-Cox) 
tests were performed to identify significant differences between vehicle and 
dabigatran treatment. All other data were analyzed by unpaired one-tailed t-tests. 
Significance was compared and reported as p ≤0.05 (*), p ≤0.01 (**), p ≤ 0.001 (***).  
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Results 
 
Toxicity Analysis  
 Throughout the experiment, fly deaths were recorded to evaluate toxicity 
related to dabigatran treatment (Figure 1). Dabigatran did not induce significant death 
in either gender or genotype. Therefore, treatment at 25 μM was regarded as safe in 
this experiment.  
 
Negative Geotaxis  
 Motor impairments in Drosophila were evaluated using the negative geotaxis 
assay (Figure 2). In male flies, LRRK2 mutants exhibited a significant reduction in 
climbing ability as compared to wildtype control, reported as 22% ±12.1 and 110.8% 
±16.8, respectively (Figure 2A). Additionally, in LRRK2 mutant flies, dabigatran 
significantly improved climbing ability to 52.2% ±7.3, as compared to transgenic 
control. Significant motor impairments were identified in LRRK2 female control flies, 
as compared to wildtype (LRRK2, 56.2% ±11.1; wildtype, 100% ±12.2) (Figure 2B). 
Dabigatran did not exhibit any significant effects as compared to control in female 
flies.  
Nitric Oxide Species Production 
 NOS production was evaluated in fly head homogenates using the Griess 
reagent (Figure 3). Interestingly, LRRK2 mutant flies did not exhibit increased NOS as 
compared to wildtype control. In male LRRK2 flies, dabigatran exhibited a significant 
reduction in NOS as compared to control (control 38.8 ±5; dabigatran 26.8 ±3.3) 
(Figure 3A). NOS was unaltered by dabigatran treatment in female LRRK2 flies 
(Figure 3B).   
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Reactive Oxygen Species  
 ROS production in fly head homogenates was also investigated (Figure 4). 
LRRK2 mutant flies did show a change in ROS production as compared to wildtype 
control. In male LRRK2 mutant flies, dabigatran significantly reduced ROS as 
compared to control (control: 455.6 ±26.8; dabigatran 351.8 ±18.4). Female LRRK2 
flies exhibited no difference in ROS production with dabigatran treatment (Figure 4B).  
Western Blot Analysis  
Tyrosine hydroxylase (TH; Figure 5) expression was significantly reduced in 
male transgenic flies (0.54  ±0.09) as compared to wildtype control (1.08 ±0.1). 
Female flies also exhibited significant loss of TH (wildtype 1.0 ±0.17; transgenic 0.69 
±0.01). Dabigatran treatment did not significantly alter TH expression in either gender.  
Inducible nitric oxide synthase (iNOS) (Figure 6) is directly related to nitric 
oxide production. Herein, we evaluated the expression of iNOS in fly head 
homogenates. Transgenic male flies exhibit increased expression of iNOS, as 
compared to wildtype control, reporting 1.6 ±0.32 and 0.89 ±0.18, respectively. 
Dabigatran treatment in transgenic male flies reduced iNOS expression, though not 
significantly. Female flies exhibited no significant differences between groups.  
Superoxide dismutase 1 (SOD1) is heavily involved in ROS production, 
herein, we evaluated protein expression by western blot (Figure 7). SOD1 was 
significantly elevated in male transgenic homogenates, as compared to wild type 
(transgenic 1.4 ±0.16; wildtype 0.68 ±0.07). Dabigatran treatment reduced SOD1 
expression to 0.84 ±0.05. Female fly homogenates followed a similar pattern. Wild 
type control flies exhibited 0.83 ±0.1, whereas transgenic control showed 1.2 ±0.09. 
In females, dabigatran treatment reduced SOD1 expression to 0.82 ±0.09.  
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NADPH oxidase 4 (NOX4) expression was evaluated in Drosophila head 
homogenates (Figure 8). Transgenic male flies exhibit significantly increased 
expression of NOX4 compared to wildtype control, reporting 1.5 ±0.06 and 1.0 ±0.03, 
respectively. Dabigatran treatment in transgenic male flies reduced NOX4 expression 
to 0.61 ±0.14. Females exhibited no significant changes in NOX4 expression.  
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Discussion 
 
 Currently, there are no treatments that stop or even slow the progression of 
neurodegenerative diseases. Therefore, it is imperative to explore novel approaches 
aside from classical targets. Neuroinflammation has been identified as a major 
contributor in AD and PD that may begin years before an official diagnosis5. Activated 
brain vasculature can lead to an increase in disease severity36–38. In PD, a variety of 
genetic mutations have recently been identified in disease pathology. One of the most 
common mutations, LRRK2, is heavily expressed in the vasculature of the brain39. It 
was hypothesized that by inhibiting the vascular protein thrombin, neuroinflammation 
would be reduced in a transgenic PD model.  
 In PD, motor impairments are the main disease identifier, typically shown by 
tremors or motor function instabilities in humans. Drosophila melanogaster models of 
PD exhibit similar motor impairments that are believed to be linked to loss of 
dopaminergic neuronal function30.  Therefore, we first assayed motor function in wild 
type and transgenic flies in the negative geotaxis assay. As anticipated, in both 
genders, a significant reduction in climbing ability was seen in the transgenic as 
compared to the wildtype control. Dabigatran treatment in male transgenic flies alone 
exhibited improvement in climbing. 
 Parkinson’s disease loss of motor control is heavily regulated by the loss of 
functional neurotransmitter dopamine. Drosophila melanogaster exhibit many 
similarities to humans, namely, there are distinct dopamine clusters that correspond 
to locomotor control, and dopamine synthesis is conserved40. Regulation of dopamine 
is limited by protein tyrosine hydroxylase (TH), which converts tyrosine to dopamine41. 
Therefore, we performed western blotting to quantify tyrosine hydroxylase expression 
in fly head homogenates to identify the correlation between TH levels and the 
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observed motor function. In transgenic male flies, there was a significant reduction in 
TH as compared to wildtype control. However, dabigatran treatment did not improve 
the levels of TH. This suggests that alternative processes may be involved. 
 The production of nitric oxide and reactive oxygen species are linked to both 
neuroinflammation and damaged cerebrovasculature in neurodegenerative 
diseases5,42,43. Dabigatran treatment has been shown to decrease oxidative stress 
markers in diseased models14,20,21. LRRK2 has also been associated with increases in 
these mediators of oxidative stress44. In Drosophila melanogaster NOS and ROS 
production can be altered with dietary modifications35,45,46. Here, surprisingly, NOS 
was reduced in transgenic flies as compared to wildtype. However, dabigatran 
treatment significantly reduced NOS production as compared to control in transgenic 
male flies. No differences were found in the females. Additionally, ROS was 
significantly reduced in male LRRK2 flies following dabigatran treatment. To further 
investigate these results, we analyzed the expression of proteins in the regulatory 
pathways of each NOS and ROS production.  
 NOS is essential to normal function, but the continuous production of NOS 
leads to excessive toxicity in the central nervous system47. iNOS is one of three 
isoforms that contributes to the production of NOS. Activated microglia induce 
cytokine activity, leading to iNOS production which has been deemed neurotoxic48,49. 
We analyzed iNOS to get a better understanding of toxic NOS production. In 
transgenic male Drosophila, iNOS expression correlates to NOS levels. Females did 
not follow a similar trend.  
 Similar to NOS, ROS is toxic when overproduced. ROS is regulated by a 
variety of mediators. We chose two markers, namely, SOD1 and NOX4. Superoxide 
dismutases are essential in the breakdown of superoxide into oxygen and hydrogen 
peroxide50. Typically, an increase in the expression of SOD1 indicates an elevation in 
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ROS. In both male and female Drosophila, SOD1 was elevated in transgenic as 
compared to wildtype. Additionally, dabigatran treatment reduced SOD1 expression. 
Interestingly, these differences did not exactly mimic identified ROS levels. In 
Drosophila melanogaster, it has been contested whether SOD directly correlates to 
ROS50. NADPH oxidases are another family of enzymes that regulate ROS 
production51. NOX4 is heavily expressed in endothelial cells and contributes directly 
to ROS production52. Male Drosophila exhibited increased NOX4 in transgenic flies. 
Additionally, dabigatran treatment reduced NOX4. Similar to SOD1, NOX4 expression 
does not directly correlate to ROS production. 
 Interestingly, our data reports differences in treatment response by gender. In 
human PD, the incidence, progression, and symptom severity present differently in 
males and females53,54. These differences have been largely attributed to hormonal 
differences55,56. Sex differences in Drosophila have frequently been overlooked. 
However, reports on lifespan indicate the potential of extreme differences between 
gender in flies57. 
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Conclusions  
 
 Here, we explore direct thrombin inhibitor, dabigatran, in a transgenic 
Drosophila melanogaster model for the first time. Our results indicate that dabigatran 
treatment improves motor function by reducing oxidative stress. Future research 
should evaluate dabigatran treatment in additional models of Parkinson’s disease, 
focusing on the progression and pathology. These initial findings should be 
investigated in alternative transgenic models of PD and evaluated for effects on 
behavior as well as biochemical markers of pathology to further elucidate 
mechanisms of action.  
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Figure 1. Analysis of treatment induced toxicity in wildtype and transgenic Drosophila 
melanogaster. Flies were exposed to sucrose or dabigatran (25 µM) over 1 week of 
treatment in males (A) and females (B) (n³100). 
  
 
132 
 
 
 
Figure 2. Effects of dabigatran on negative geotaxis in Drosophila melanogaster. 
Male (A) and female (B) flies were evaluated on negative geotaxis after seven days of 
treatment (n³8). Data expressed as percent of wildtype control, significance 
determined by t-test, p ≤0.05 (*); p ≤ 0.001 (***).  
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Figure 3. Evaluation of nitric oxide species production in Drosophila melanogaster 
head homogenate. Male (A) and female (B) homogenates treated for 1 week with 
control or dabigatran (25 µM) (n³8). Statistical significance determined by t-test, p 
≤0.05 (*). 
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Figure 4. Effects of dabigatran (25 µM) on reactive oxygen species production in 
wildtype and transgenic Drosophila melanogaster. Head homogenates in males (A) 
and females (B) after 1 week treatment (n³8). Significance determined by t-test, p ≤ 
0.01 (**).  
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Figure 5. Quantification of tyrosine hydroxylase (TH) by western blot in Drosophila 
melanogaster head homogenates. Expression was evaluated in male (A) and female 
(B) homogenates after 1 week of control or dabigatran treatment (n³3). Significance 
determined by t-test, p ≤ 0.05 (*); p ≤ 0.01 (**). 
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Figure 6. Western blot analysis of inducible nitric oxide synthase (iNOS) in 
Drosophila melanogaster head homogenate. Control or dabigatran (25 M) treatment 
for 1 week in males (A) and females (B) (n³3). Statistical significance was determined 
by t-test, p ≤ 0.01 (**). 
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Figure 7. Superoxide dismutase 1 (SOD1) expression in Drosophila melanogaster. 
Evaluation of SOD1 after 1 week treatment with control or dabigatran in male (A) and 
female (B) Drosophila (n³3). Statistical significance was determined by t-test, p ≤ 
0.05 (*);p ≤ 0.01 (**). 
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Figure 8. Evaluation of NADPH (NOX4) by western blot in Drosophila melanogaster. 
Male (A) and female (B) flies were subject to treatment for 1 week (n³3). Statistical 
significance was determined by t-test, p ≤ 0.01 (**); p ≤ 0.0001 (***). 
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Abstract 
 
Background. Thrombin is neurotoxic and is elevated in the brain and 
cerebrovasculature in Alzheimer’s disease (AD). We have identified thrombin as a 
key mediator of vascular inflammation in AD with data demonstrating that thrombin 
inhibition is protective in an amyloid based animal model. Here, we investigate the 
role of thrombin as a pathological mediator in a tau-based animal model of AD. We 
hypothesize that thrombin inhibition will reduce oxidative stress, inflammation, and 
pathology related to tau in vivo.  
Methods. 15-month-old Tg4510 mice were treated with the direct thrombin inhibitor 
dabigatran etexilate or control for 7 days. Brains were collected, and western blot and 
LC-MS/MS SWATH analysis were performed to evaluate proteins related to 
coagulation, oxidative stress, intracellular signaling, and tau-pathology.  
Results. Dabigatran etexilate treatment reduces thrombin and thrombin-related 
proteins. MAPK related proteins exhibited significant differences following dabigatran 
etexilate treatment. Treatment also reduced oxidative stress-related proteins and 
increased expression of antioxidant proteins. Total tau and related phosphorylated 
tau species were significantly increased in transgenic mice compared to wild type. 
Dabigatran treatment slightly reduced expression of total tau and significantly altered 
the tau phosphorylation pattern. Proteins identified as downregulated in human AD 
were also significantly altered with dabigatran treatment compared to control.  
Conclusions. Taken together, these data indicate short-term treatment with a direct 
thrombin inhibitor modulates protein expression in the brains of aged Tg4510 mice. 
This finding supports our hypothesis that targeting thrombin, a key mediator of 
neuroinflammation and neurotoxicity may be effective in reducing AD-related 
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pathology. Further studies are needed to better understand the mechanisms of action 
and possible neuroprotective benefits of thrombin inhibition.   
 
Keywords: Alzheimer’s disease, Inflammation, Oxidative Stress, Thrombin, Tau 
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Introduction 
 
Cardiovascular disease and cardiovascular risk factors (CVRFs) are strongly 
associated with an increased risk of developing dementia, particularly Alzheimer’s 
disease (AD). Hypertension, hypercholesterolemia, hyperhomocysteinemia, diabetes, 
atherosclerosis, and hypoxia are all linked with an increased risk of developing AD [1-
5]. While the connection between CVRFs and AD is well-documented, the 
mechanism by which the disorders are connected is not well understood. It is likely 
there are several, pathological mediators involved in the progression of both 
disorders.  
One such mediator is the serine protease thrombin, the main driver of the 
coagulation cascade [6]. Thrombin is indicated as a potential pathological mediator in 
both cardiovascular disease and AD. Thrombin has been implicated in 
atherosclerosis and diabetes-related pathology [7-11]. Thrombin is also elevated in 
the Alzheimer’s brain. Past studies found increased thrombin and reduced levels of 
the thrombin inhibitor protease nexin-1 in the brain of Alzheimer’s patients compared 
to healthy controls; this elevation was largely localized in vessels, amyloid deposits, 
and neurofibrillary tangles [12-14]. Thrombin is also elevated in AD patient-derived 
microvessels, and brain endothelial isolated from AD patients synthesize their own 
thrombin [15, 16]. Thrombin is a mediator of vascular-derived oxidative stress and 
inflammation. Aside from its pro-coagulant activity, thrombin has well-documented 
pro-inflammatory and pro-oxidative effects on several cell types in the body, largely 
through its activation of protease-activated receptors (PARs) [17, 18]. In the 
periphery, increased thrombin in disease is related to the formation of atherosclerotic 
plaques, endothelial cell activation, and an increase in both inflammatory cytokines 
and reactive oxygen species (ROS) [7, 19-21].  
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Thrombin has similar effects in the brain as it does in the periphery. Thrombin 
treatment induces alteration of endothelial cell phenotype at the blood-brain barrier 
(BBB), leading to changes in adhesion and tight junction formation [22, 23]. Thrombin 
also stimulates endothelial cells to release inflammatory factors and ROS; similar 
increases are found in the AD cerebrovasculature [15, 24-29]. Thrombin treatment of 
microglia induces a pro-inflammatory phenotype characterized by increases in ROS, 
NO, and cytokine production [30-33]. Thrombin is also associated with increased pro-
inflammatory, reactive astrocytes in the brain [34-37]. Additionally, thrombin exerts 
direct neurotoxicity by several mechanisms, including alterations in the neuronal cell 
cycle, induction of pro-apoptotic proteins, and NADPH-oxidase mediated oxidative 
stress [38, 39].  
Thrombin is also associated with AD-related hallmarks in the brain, including 
tau, amyloid aggregation, and apolipoprotein E [40-44]. Rats treated with thrombin in 
vivo exhibit cognitive deficits along with cell death and glial scarring [35]. Thrombin 
may be involved in the altered processing and secretion of amyloid precursor protein 
(APP), and thrombin cleavage of apolipoprotein E4 results in a neurotoxic fragment 
[42-44]. Thrombin accumulation has been identified in neurofibrillary tangles, and 
thrombin induces rapid tau aggregation [40, 41].  
Thrombin is related to altered processing and aggregation of tau, but the role 
of thrombin as a pathological mediator has not yet been explored in a tau-based 
model of AD.  Currently, a number of tauopathy animal models are being used to 
study AD. One such model is the Tg4510, which overexpresses human tau with a 
P301L mutation at 13:1 versus murine tau [45]. These mice exhibit profound tau 
pathology and neuronal loss in the hippocampus and cortex, as well as cognitive 
deficits and metabolic changes. The pathology starts early at about 2 to 4 months of 
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age and progresses with age [45, 46]. The pathological features, including tau 
hyperphosphorylation synapse loss, are more pronounced in females than males 
[47].  Additionally, the tg4510 mouse model displays blood vessel abnormalities 
accompanied by alterations in oxidative and inflammatory markers [48].  
We suggest that thrombin is a mediator of cerebrovascular-derived 
inflammation and neurotoxicity in AD, and therefore targeting thrombin may be a 
worthy therapeutic strategy to combat Alzheimer’s disease-related pathology. Our lab 
has focused on the direct thrombin inhibitor Dabigatran etexilate (Pradaxa®, 
Boehringer Ingelheim), a commonly prescribed anticoagulant that is administered 
orally. In a previous paper, we identified that dabigatran etexilate treatment for 34 
weeks in 3xTg AD mouse model reduced levels of oxidative stress and markers of 
cerebrovascular inflammation in the brain [49]. 
The objective of this study is to investigate the role of thrombin as a 
pathological mediator and the potential therapeutic benefits of inhibiting thrombin in 
an animal model of tauopathy and AD. We explore the effects of short-term treatment 
with direct thrombin inhibitor, dabigatran etexilate, in aged Tg4510 mice. We 
hypothesize that that inhibiting thrombin will reduce oxidative stress and 
inflammation-related indicators corresponding to an overall reduction in tau-related 
dysfunction in the brain.  
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Materials and Methods 
 
Animals and Treatment 
Transgenic Tg4510 AD mice overexpressing human mutant tau (P301L) and 
background matched controls were a kind gift from MindImmune Therapeutics, Inc. 
originally obtained from Charles River (Wilmington, MA, USA). Mice were maintained 
on normal chow (ENVIGO 2020X, Huntingdon, UK) with water available ad libitum. At 
15 months of age, mice were treated via oral gavage with vehicle (2.5% DMSO, 2.5% 
koliphor EL, 90% diH2O) or dabigatran etexilate (100 mg/kg in uniform suspension, 
Cayman Pharm, Ann Arbor, MI) for 7 days. After 7 days, mice were deeply 
anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) administered I.P. and 
euthanized.  
Western blot 
Whole brains were removed post-sacrifice and the cerebellum was detached. 
Tissues were homogenized by sonication (Branson SX150 Sonifier ®, Branson 
Ultrasonics, Danbury, CT) in 9x brain volume of 1X PBS with protease inhibitors. To 
prepare samples for western blot, samples were mixed with equal parts 2x Sample 
Buffer (4x Laemmli sample buffer with 10% 2-mercaptoethanol, 50% diH2O) and 
heated at 100°C for 10 minutes. Samples containing 25 µg total protein were loaded 
on a 4-20% Gel (NOVEX) that was run at 105 V for 1 hour and 5 minutes in 1x SDS-
running buffer. Proteins were then transferred to nitrocellulose membranes using 
iBlot2 Gel Transfer Device (ThermoFisher Scientific, Waltham, MA). Membranes were 
blocked using antibody-specific concentration of BSA or Milk in 0.05% TBS-T for one 
hour. Primary antibodies for this study include thrombin (Abcam, MA; 1:500), fibrin 
(Santa Cruz, CA; 1:250), NOX4 (Sigma, MA; 1:1,000), iNOS (Abcam, MA; 1:250), 
SOD1 (Abcam, MA; 1:1,000), SOD2 (Abcam, MA; 1:2,000), GFAP (Abcam, MA; 
 
 
152 
 
 
1:10,000), Iba1 (GeneTex, CA; 1:1,000). Tau and p-tau species were detected using 
phosphor-tau family antibody sampler kit (Cell Signaling, MA). Primary antibodies 
were added overnight at 4°C. Membranes were washed three times for 5 minutes 
with 0.05% TBS-T and incubated with infrared secondary antibodies for 1 hour at 
room temperature. Membranes were washed as before and then imaged on a LiCor 
Odyssey (LI-COR Biosciences, Lincoln, NE). Quantification of western blots was 
done in ImageJ. Values for each protein were normalized to actin or GAPDH loading 
control on the same blot. Data represented as fold change, as compared to TgV.  
Pressure Cycling Technology Based Protein Digestion  
Whole brain homogenates were further digested using pressure cycling 
technology (PCT) for LC-MS/MS SWATH acquisition following the method by Jamwal 
et al. 2017 with slight modifications [50]. Each sample, containing 500 µg of protein, 
was spiked with 2 ng of bovine serum albumin (BSA). Samples were then incubated 
with dithiothreitol (100 mM) at 90°C for 15 minutes (100 rpm). Iodoacetamide (200 
mM) was added and samples were incubated at room temp in the dark for 30 
minutes. Protein was then precipitated by using the ice-cold chloroform, methanol 
and water method (1:2:1) followed by centrifugation at 12,000 RPM for 5 minutes at 
10°C. The protein pellet was rinsed with methanol and resuspended in 3% w/v 
sodium deoxycholate (DOC) in 50 mM ammonium bicarbonate. Samples were placed 
in MicroTubes (Pressure BioSciences Inc, South Easton, MA) with trypsin at a 1:20 
ratio of trypsin:protein. Digestion was performed at 55°C for 75 cycles (50 sec at 
35kpsi, 10 sec at ambient pressure) in a Barocycler NEP2320-45k (Pressure 
BioSciences Inc). A second digestion was performed by adding fresh trypsin at the 
same ratio and running the barocycler for an additional 60 cycles. Samples were then 
transferred to microcentrifuge tubes where digestion was stopped and DOC was 
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precipitated by the addition of formic acid in acetonitrile at a final percentage of 0.5%. 
Samples were centrifuged and supernatant was collected for analysis.  
Mass Spectrometry Data Acquisition with SWATH-MS  
Mass spectrometry was performed as previously described with minor 
modifications [50]. Samples were analyzed on a SCIEX TripleTOF® 5600 mass 
spectrometer using a DuoSpray™ ion source (SCIEX, Framingham, MA) coupled to 
an Acquity HClass UHPLC system (Waters Corp., Milford, MA).  Separation was 
achieved on an Acquity UPLC Peptide BEH C18 column (2.1 x 150 mm, 300 Å, 1.7 
µm) with an Acquity VanGuard pre-column (2.1 x 5 mm, 300 Å, 1.7 µm). The column 
temperature was set to 50˚C and the autosampler was set to 10˚C.  A linear gradient 
was used with a flow rate of 100 µL/min for 90 min. Mobile phase A consisted of 
99.9% acetonitrile and 0.1% formic acid.  Mobile phase B consisted of 99.9% water 
and 0.1% formic acid.  The gradient was as follows: 98% A from 0 to 5 min, 98% to 
75% from 5 to 55 min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 70 
min.  Mobile phase A was held at 20% from 70 to 75 min and returned to 98% A at 80 
min.  The column was held at 98% A for 10 min to equilibrate prior to the next sample.  
A mixture of trypsin-digested β-galactosidase peptides were used between every 8 
samples to calibrate masses and monitor the TOF detector. 
Positive ionization mode was used for data dependent acquisition. The mass 
spectrometer parameters are as follows: gas 1, gas 2, curtain gas, temperature and 
ion spray voltage floating were 55 psi, 60 psi, 25 psi, 450˚C, 5500 V, Respectively. 
Declustering potential was 10, collision energy 10 and collision energy spread 15. For 
data acquisition, a maximum of 50 candidate ions were monitored for each survey 
scan.  All ions had a charge state from 2 to 4.  A range of m/z 300-1250 was used for 
exclusion criteria and all ions that had an intensity greater than 25 cps were chosen 
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for MS/MS analysis. The temperature was set at 450˚C and the total cycle time was 
3.5 sec with a mass tolerance of 50 mDa during the first 0.75 sec survey scan. 
For SWATH analysis, all parameters were the same as above except for the 
following:  Seventy SWATH windows per cycle were collected over m/z 400-1100 with 
each window size being m/z 10 and TOF masses were collected from m/z 300 to 
1500. 
Mass Spectrometry Data Analysis  
LC-MS/MS SWATH data was used to generate spectral libraries through 
ProteinPilot (SCIEX, Framingham, MA).  Proteins of interest were identified and 
investigated. FASTA files were downloaded from UniProt and imported into Skyline 
(MacCoss Lab, University of Washington). In Skyline, at least 3 transitions were 
selected per peptide, and at least 3 peptides per protein were chosen. Once data was 
analyzed, the MPPreport (MacCoss Lab, University of Washington) was generated 
and exported to excel. In excel, transitions were averaged, and the sum of each 
peptide was calculated to yield the total area under the curve representative of each 
protein. These were then standardized to internal standard, BSA.  
Statistical analysis 
Data from each experiment are expressed as mean +/- standard error (SEM), 
unless otherwise indicated. All tests were performed in GraphPad prism. Analysis 
was done by unpaired, one-tail t-test. Statistical significance was determined at 
p<0.05. Significance for all tests was defined as follows: p £ 0.05 (*), p £ 0.01 (**), p £ 
0.001 (***), and p £  0.0001 (****). 
 
 
155 
 
 
Results 
One-week dabigatran etexilate treatment reduces expression of coagulation related 
proteins 
The expression of major proteins involved in coagulation, namely, thrombin, 
prothrombin and fibrin were evaluated by western blot. Thrombin levels remained 
unaltered in wild type as compared to Tg-Vehicle. Although not significant, dabigatran 
treatment decreased thrombin by 33% as compared to Tg-Vehicle (Figure 1A). 
Prothrombin was significantly lower in wild type mice by 44% compared to Tg-Vehicle 
(Figure 1B). Dabigatran treatment significantly reduced prothrombin by 46.7% as 
compared to Tg-Vehicle. Fibrin levels were slightly reduced in both wildtype (54.9%) 
and dabigatran etexilate (44.4%) as compared to Tg-Vehicle (Figure 1C).  
Dabigatran etexilate reduces oxidative-stress related proteins  
Inducible nitric oxide synthase (iNOS) and NADPH oxidase 4 (NOX4) are 
enzymes involved in the activation of oxidative stress by catalyzing the production of 
NOS and ROS. The expression of iNOS was significantly reduced in wild type and 
Tg-Dabigatran, as compared to Tg-Vehicle by 23.5% and 17.4%, respectively (Figure 
2A). Tg-Dabigatran also significantly reduced NOX4 expression by 24.7% as 
compared to Tg-Vehicle (Figure 2B).  
Dabigatran etexilate increases expression of superoxide dismutases  
Expression of antioxidant related proteins, superoxide dismutase 1 (SOD1) 
and superoxide dismutase 2 (SOD2) was also evaluated by western blot (Figure 3). 
No differences were reported between wild type and Tg-Vehicle. Tg-Dabigatran 
significantly increased the expression of both SOD1 and SOD2 by 34.2% and 20.7%, 
respectively.  
Effect of Dabigatran etexilate on neuroinflammatory proteins 
 
 
156 
 
 
Glial fibrillary acidic protein (GFAP) and ionized calcium binding adaptor 
molecule 1 (IBA1) are markers of activated astrocytes and microglia, respectively. 
These neuroinflammatory markers were significantly elevated in Tg-Vehicle as 
compared to wild type mice (Figure 4). Tg-Dabigatran exhibited slightly lower GFAP 
(0.78 ±0.12) and Iba1 (0.95 ±0.12) expression than Tg-Vehicle, but reductions were 
not significant.  
Dabigatran etexilate treatment alters tau phosphorylation but not overall expression 
Total tau and phosphorylated forms S396, S404 and S416 were evaluated by 
western blot (Figure 5). Tg-Vehicle expressed 75.9% more total tau than wild type 
mice (Figure 5A). Tg-Dabigatran exhibited 22.1% less total tau as compared to Tg-
Vehicle. Wild type mice exhibited significantly lower levels of all three phosphorylated 
tau forms. Tg-Dabigatran showed decreased levels of S396 and S416, by 32.8 and 
29.2%, respectively. Interestingly, S404 was elevated by 14.9% in Tg-Dabigatran, as 
compared to Tg-Vehicle.  
LC-MS/MS SWATH acquisition identifies significant proteomic differences between 
wild type and Tg-Vehicle mice  
Major proteins involved in coagulation, AD, inflammation and tau-related 
pathology were identified and evaluated using LC-MS/MS SWATH acquisition (Table 
1). Significant differences in protein expression were first evaluated between wildtype 
and transgenic mice, visualized with a volcano plot (Figure 6A). Coagulation related 
proteins exhibited significant differences in FIBB, ICAM5, KPCD, MMP9, and RACK1. 
Differences were seen in inflammation related proteins DLG4, GFAP, NOS3 and 
TLR4. Alzheimer’s disease related proteins that were significantly altered in Tg4510 
mice were A4, APOE, BACE1, TAU (Human), TAU (Mouse), and TAU (Total). A 
recent publication identified proteomic signatures in the human brain affected by tau 
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pathology (Mendoça, 2019). From this publication we identified a list of tau-related 
pathology proteins and explored these differences. Wildtype to Tg4510 brains 
exhibited significant differences in G6PD1, HPCA, KCC2A, NAC2, SV2B, TBB3 and 
VIME.  
LC-MS/MS SWATH Acquisition identifies significant proteomic expression between 
vehicle and dabigatran etexilate treated transgenic mice  
Alzheimer’s disease, coagulation, inflammation and Tau-related identified 
proteins were further evaluated to identify differences between vehicle and dabigatran 
etexilate treated transgenic mice (Figure 6B). The pathway most influenced by 
dabigatran etexilate treatment was the coagulation cascade. Significant differences 
were seen in ANT3, ICAM1, ITAL, ITB2, KPCB, KPCD, MK08, MK09, MP2K1, 
MP2K2, ROCK2 and VCAM (Figure 7A). Inflammatory proteins were also significantly 
altered, namely, COX2, DLG4, and DYN1 (Figure 7B). BACE1 was the single altered 
protein from the group of AD-related proteins. Significant differences were seen in 
Tau-related proteins, ANS1B, G3BP2, HPCA, NCKP1, SV2B, SYGP1 and TBB3 
(Figure 7C).  
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Discussion  
 
Increasing evidence has shown elevated levels of thrombin and thrombin-
related proteins of the coagulation cascade in the brains of Alzheimer’s disease 
patients [12-14, 40-44, 51]. Further, thrombin accumulation is co-localized with tau 
aggregation [40, 41]. Herein, we propose that inhibiting thrombin in a tau-pathology 
mouse model may identify an alternative approach to combat Alzheimer’s disease-
related pathology. 
Our data shows the efficacy of treatment with a direct thrombin inhibitor, 
dabigatran etexilate, in a tau mouse model. As expected, the drug treatment reduces 
thrombin and proteins increased by thrombin activity (prothrombin, fibrin), confirming 
normal drug action. In addition to coagulation, dabigatran etexilate treatment also 
produced alterations in the expression of proteins involved in oxidative stress, 
inflammation, and tau-related pathology. These results suggest that inhibition and 
reduction of thrombin may affect aspects of AD pathology through the alteration of 
different thrombin-mediated signaling mechanisms in the brain.  
Thrombin’s pro-inflammatory effects throughout the body, including in the 
brain, are largely mediated through the signaling of its receptors, protease-activated 
receptors (PARs) 1, 3, and 4. PARs represent a unique family of G-protein coupled 
receptors that are activated by a self-ligand [17]. PARs have been found in a number 
of cell types in the periphery and the brain, including endothelial cells, neurons, 
astrocytes, and microglia [52]. When cleaved and activated by thrombin, PAR1 
initiates a variety of intracellular signaling. Among others, PAR1 activates the 
mitogen-activated protein kinase (MAPK) pathway which can lead to cell growth, 
proliferation or migration [53]. MAPK related proteins were analyzed by LC-MS/MS 
SWATH analysis, identifying significant differences between Tg-Vehicle and Tg-
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Dabigatran etexilate in ANT3, ITB2, KPCB, MK08, MP2K1 and MP2K2. Interestingly, 
Dabigatran etexilate treatment did not alter proteins to wild type levels.  
Thrombin activation of PARs is responsible for pro-inflammatory and oxidative 
effects in both the periphery and brain. Here, we identified significantly elevated 
levels of iNOS, GFAP, and IBA1 in transgenic mice as compared to wild type. 
Dabigatran etexilate treatment reduced iNOS, and NOX4, as compared to vehicle. 
Dabigatran etexilate significantly increased COX2, DYN1, SOD1, and SOD2. These 
increases may be due to the timing in the antioxidant cycle [54].  Together, these 
results indicate a shift towards reduced oxidative stress following dabigatran etexilate 
treatment.  
Total tau and related phosphorylated (S396, S404, S416) tau species were 
significantly increased in transgenic mice compared to wild type, as was expected. 
Dabigatran treatment slightly reduced expression of total tau, significantly decreased 
S396, S416; but led to an increase in S404. S396 and S404 phosphorylation are 
found early in the disease course of AD [55, 56] and are related to destabilization of 
microtubules [57, 58]. S396 is also linked with abnormal truncation of the tau protein, 
indicating altered functionality [55]. Phosphorylation at S416 by CamKII is largely 
found within the neuronal soma, rather than localized to microtubules, and has been 
found to be associated with the promotion of AD-related cell death [59, 60]. Together, 
our findings indicate that dabigatran etexilate treatment may reduce AD-related tau 
dysfunction through altered phosphorylation, particularly decreased phosphorylation 
at S396 and S416.  
To further explore tau pathology, we performed LC-MS/MS SWATH analysis 
on a variety of previously identified tau related proteins. ANS1B, NCKP1, SV2B and 
SYGP were significantly altered with dabigatran etexilate treatment, compared to Tg-
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Vehicle. These proteins were previously found to be downregulated in tau pathology 
in AD brains across multiple proteomic studies [61]. These data indicate additional 
changes in tau-related dysfunction following dabigatran etexilate treatment.  
It’s important to note that there may be alternative explanations for the effects 
seen with dabigatran etexilate treatment, particularly for the decreased expression of 
oxidative and inflammatory mediators. Fibrin, a coagulation protein found 
downstream of thrombin, has also been identified as a potential pathological mediator 
in Alzheimer’s disease [62]. Higher levels of fibrin have been identified in the AD brain 
compared to healthy controls [51]. Fibrin accumulation in AD, similar to thrombin, has 
been linked with increases in inflammation and oxidative stress, as well as alterations 
in both amyloid and tau pathology [62]. Our findings showed a decrease in fibrin 
expression as a result of dabigatran etexilate treatment, which is expected given 
thrombin catalyzes the conversion of fibrinogen into fibrin. It is possible that some of 
the other changes identified with dabigatran etexilate treatment, including decreases 
in oxidative stress-related and inflammatory proteins, are the result of decreased 
fibrin accumulation rather than reduced thrombin signaling activity.  
Alternatively, there are anti-coagulant proteins, such as activated protein C 
(APC), that act in opposition to thrombin. These proteins may alternatively catalyze 
PARs and subsequently alter the signaling mechanism activated, producing anti-
inflammatory and cytoprotective effects [63]. Further studies have shown anti-
inflammatory effects of APC-like ligands mediated through PAR signaling [64]. Just as 
reduced thrombin activity may result in reduced fibrin accumulation and therefore 
reduced inflammation, reduced levels of thrombin may allow for APC and other anti-
coagulant proteins to bind to PARs and activate anti-inflammatory signaling 
processes.  
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Thrombin has increasingly become a protein of interest in Alzheimer’s, with 
other investigators also investigating thrombin as a potential pathological mediator in 
AD, and therefore a potential therapeutic target. Studies have found that indirect 
thrombin inhibitors, such as warfarin, exert anti-inflammatory and neuroprotective 
effects in models of AD [65]. However, direct thrombin inhibition with dabigatran 
etexilate may be a safer treatment option, with a reduced risk of intracerebral 
hemorrhage [66].  In a longitudinal, community-based study use of dabigatran 
etexilate was associated with a lower risk of new-onset dementia compared to 
warfarin [67]. More recently, treatment with dabigatran etexilate TgCRND8 transgenic 
AD mice improved spatial memory deficits, reduced neuroinflammation and amyloid 
plaque formation [68]. These studies demonstrate beneficial effects of thrombin 
inhibition in AD models, further supporting our hypothesis that targeting thrombin, a 
key mediator of vascular inflammation and neurotoxicity, may be effective in reducing 
AD-related pathology. 
While these findings are interesting, it is worthy to note that this study is 
limited in scope. The cohort analyzed was made up of a specific gender at a late age 
for a short treatment time. Future studies should analyze longer dabigatran etexilate 
treatment at various life stages to better identify the best time and length for 
pharmaceutical intervention for the alteration of AD-related pathology.  
Here, we investigate the role of thrombin as a pathological mediator in 
Alzheimer’s disease, and the efficacy of a direct thrombin inhibitor, dabigatran 
etexilate, in a transgenic tau-based AD mouse model. After seven days of treatment, 
dabigatran etexilate treatment altered proteins related to coagulation, inflammation, 
oxidative stress and tau pathology. Further, data suggests that thrombin inhibition 
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may mediate AD pathology through multiple thrombin-mediated signaling 
mechanisms.  
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Table 1. List of proteins and corresponding abbreviations. Proteins analyzed in 
Skyline, data obtained by LC-MS/MS with SWATH acquisition.  
 
 
Pathway  Abbreviation Full Protein Name 
A
l]
he
im
er
¶
V 
D
is
ea
se
 
A4 Amyloid-beta A4 protein (ABPP) (APP)  
APOE Apolipoprotein E (Apo-E) 
BACE1 Beta-secretase 1  
BACE2 Beta-secretase 2  
TAU (Human) Microtubule-associated protein tau  
TAU (Mouse) Microtubule-associated protein tau  
TTBK2 Tau-tubulin kinase 2  
C
oa
gu
la
tio
n 
C
as
ca
de
 
ANT3 Antithrombin-III 
FA5 Coagulation factor V (Activated protein C cofactor) 
FA8 Coagulation factor VIII (Procoagulant component) 
FA10 Coagulation factor X 
FIBA Fibrinogen alpha chain 
FIBB Fibrinogen beta chain 
ICAM1 Intercellular adhesion molecule 1 
ICAM5 Intercellular adhesion molecule 5 
ITAL Integrin alpha-L 
ITAM Integrin alpha-M 
ITAV Integrin alpha-V  
ITB2 Integrin beta-2  
ITB3 Integrin beta-3 
KPCA Protein kinase C alpha type  
KPCB Protein kinase C beta type  
KPCD Protein kinase C delta type  
MK01 Mitogen-activated protein kinase 1 
MK03 Mitogen-activated protein kinase 3  
MK08 Mitogen-activated protein kinase 8 
MK09 Mitogen-activated protein kinase 9 
MMP2 Matrix metalloproteinase-2; 72 kDa type IV collagenase  
MMP9 Matrix metalloproteinase-9  
MP2K1 Dual specificity mitogen-activated protein kinase kinase 1  
MP2K2 Dual specificity mitogen-activated protein kinase kinase 2 
RACK1 Receptor of activated protein C kinase 1  
ROCK1 Rho-associated protein kinase 1  
ROCK2 Rho-associated protein kinase 2  
VCAM1 Vascular cell adhesion protein 1 
In
fla
m
m
at
io
n 
R
el
at
ed
 
CDK5 Cyclin-dependent-like kinase 5  
COX2 Cytochrome c oxidase subunit 2  
DLG4 Disks large homolog 4  
DYN1 Dynamin-1  
GFAP Glial fibrillary acidic protein (GFAP) 
MILK2 MICAL-like protein 2  
NFKB1 Nuclear factor NF-kappa-B p105 subunit 
NOS3 Nitric oxide synthase, endothelial  
PARK7 Protein/nucleic acid deglycase DJ-1  
PTPRC Receptor-type tyrosine-protein phosphatase C  
TLR4 Toll-like receptor 4  
Ta
u 
R
el
at
ed
  
ACTN2 Alpha-actinin-2  
ANS1B Ankyrin repeat and sterile alpha motif domain-containing protein 1B (Amyloid-beta protein intracellular domain-associated protein 1) 
G3BP2 Ras GTPase-activating protein-binding protein 2 
G6PD1 Glucose-6-phosphate 1-dehydrogenase X  
GNAZ Guanine nucleotide-binding protein G(z) subunit alpha 
HPCA Neuron-specific calcium-binding protein hippocalcin 
KCC2A Calcium/calmodulin-dependent protein kinase type II subunit alpha  
NAC2 Sodium/calcium exchanger 2 
NCKP1 Nck-associated protein 1  
PACN1 Protein kinase C and casein kinase substrate in neurons protein 1 (Syndapin-1) 
Q8CFX3 Protocadherin 1 
SV2B Synaptic vesicle glycoprotein 2B  
SYGP1 Ras/Rap GTPase-activating protein SynGAP 
TBB3 Tubulin beta-3 chain 
TLN1 Talin-1 
VIME Vimentin 
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Figure 1. One-week dabigatran etexilate treatment reduces expression of 
coagulation-associated proteins in Tg4510 mouse brain.  Western blot evaluation of 
expression for proteins involved in coagulation, namely, thrombin (A), prothrombin (B) 
and fibrin (C). All data expressed as mean ± standard error (n=4-6), significance reported 
by t-test, *p £ 0.05, **p < 0.01, ***p < 0.001. 
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Figure 2. One-week dabigatran etexilate treatment reduces expression of 
oxidative-stress related proteins in Tg4510 mouse brains.  Evaluation of expression 
of oxidative stress proteins by western blot, iNOS (A) and NOX4 (B). All data expressed 
as mean ± standard error (n=4-6), significance reported by t-test, *p £ 0.05, **p<0.01.  
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Figure 3. One-week dabigatran etexilate treatment increases expression of 
antioxidant proteins in Tg4510 mouse brain.  Western blot analysis of antioxidant 
proteins SOD1 (A) and SOD2 (B). All data expressed as mean ± standard error (n=4-6), 
significance reported by t-test, *p £ 0.05, ****p £ 0.0001. 
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Figure 4. Dabigatran etexilate treatment does not alter expression of 
neuroinflammation-associated proteins in Tg4510 mouse brain.  Investigation of 
proteins involved in neuroinflammation by western blot GFAP (A) and IBA1 (B). All data 
expressed as mean ± standard error (n=4-6), significance reported by t-test, ***p £ 0.001; 
****p £ 0.0001.  
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Figure 5. Evaluation of total Tau, and phosphorylated protein expression by 
western blot. Total Tau (A), phosphorylated Tau at sites S396 (B), S404 (C) and S416 
(D). All data expressed as mean ± standard error (n³4), significance reported by t-test, *p 
£ 0.05, **p £ 0.01; **** p £ 0.0001 (****).  
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Figure 6. Volcano plots comparing LC-MS/MS SWATH data of wild type mice to 
Tg-Vehicle (A) and Tg-Vehicle to Tg-Dabigatran (B). All data expressed as fold 
change (n=5).   
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Figure 7. LC-MS/MS SWATH data analyzed for coagulation (A), inflammation (B) 
and tau-pathology related (C). Data expressed as fold change (n=5).  
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CONCLUDING REMARKS 
 
An exponential increase in the prevalence of neurodegenerative diseases has 
led to a worldwide health crisis. The two most common neurodegenerative diseases, 
Alzheimer’s and Parkinson’s disease constitute the largest majority of cases. 
Although research has been ongoing, no successful interventions have been 
discovered that stop the progression of the disease. Focus has shifted from targeting 
disease characteristic protein aggregations, namely b-amyloid and a-synuclein, to 
identifying targets earlier in disease progression, such as neuroinflammation or 
cognitive decline. Herein, we utilize two independent strategies: the use of natural 
products and repurposed pharmaceuticals to target neuroinflammation in models of 
Alzheimer’s and Parkinson’s disease.  
 Natural products have been utilized for centuries in traditional medicines to 
combat a wide variety of illnesses. The therapeutic potential of thousands of plants 
has yet to be fully elucidated, posing a major source of untapped resources. Our 
research analyzed Mucuna pruriens and a common class of plant compounds, 
polyphenols, for their protective effects against neuroinflammation and potential as 
nutraceutical interventions. A levodopa-reduced Mucuna pruriens seed extract 
exhibited protective effects against toxin-induced inflammation and neuronal death. 
After isolation, no single compound exhibited these protective effects, supporting a 
potential synergistic effect in the extract. Further, polyphenol microbial metabolites, 
but not parent compounds showed protective effects in vitro against toxins. Equol, a 
gut-derived metabolite, was also effective in vivo against Parkinson’s disease-specific 
toxic agents. These natural products exhibit protective effects in Parkinson’s disease 
models, suggesting potential therapeutic in neurodegenerative diseases.  
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 A newer approach to identify new therapeutics is to repurpose previously 
approved pharmaceuticals for new indications. Repurposing pharmaceuticals is a 
drug discovery approach that may fast track pharmaceuticals to a new targeted 
patient population. We analyzed direct thrombin inhibitor, dabigatran etexilate 
(Pradaxa®), against neuroinflammation in AD and PD models. In a transgenic 
Drosophila melanogaster model of Parkinson’s disease, dabigatran improved motor 
control, related to the reduction in neuroinflammation as exhibited by decreased 
levels of reactive oxygen and nitric oxide species. Short-term treatment with 
dabigatran in a transgenic tau-based animal model of Alzheimer’s disease alters 
protein expression. These studies identify that repurposed pharmaceuticals may be 
effective in reducing neuroinflammation in neurodegenerative diseases.  
 While our results indicate these interventions may reduce neuroinflammation 
in models of neurodegeneration, extensive research is still necessary. Further 
elucidation of the mechanism of action in additional animal models is necessary 
before clinical trials can be conducted. Realistically, these natural products may be 
extremely far from reaching the clinic. However, dabigatran may be much closer to 
the targeted population. Moreover, these results support our initial hypothesis that 
natural products and repurposing pharmaceuticals are strategies that can target 
neuroinflammation in neurodegenerative diseases.  
 
 
 
